LOW conviction · 542 dossiers

The 2026-08-04 bounce failed: ARCB lost the $136 shelf on a 2026-08-06 close of $135.25 and printed a post-print low of $134.75 on 08-07, while three open-market director sales — the first of 2026 — executed at $138.71–$144.85 on 08-04 and…

Q1 FY27 (2026-07-29) beat, but Q2 royalty growth was guided to ~13% from the 22% delivered, on memory-driven handset weakness. The 2026-08-04 +17.36% snapback to $280.56 lifted price above six of nine published post-print targets and to…

The 2026-08-04 spectrum re-rating gap has largely round-tripped: $106.35 close, then $99.41, $100.32 and $99.26 through 2026-08-07, heaviest volume on the down day. The 1.0M-share dilution vote passed on 2026-08-04; the 2026-08-11 Q1…

Post-print recovery extended: $65.77 close on 2026-08-07 (+2.45%), above the 20-day and 50-day levels marked on 08-04, with the $69.36 52-week high in view. Two dated events inside four sessions — CMS's 3:00pm EDT 2026-08-12 PY2027 rate…

Beat-and-raise sold hard: $430.16 on 08-05 to $317.93 on 08-07, -26.1% in two sessions on the window's heaviest volume, while four brokers raised targets to $449–$490 on 08-06. Growth intact (FY26 guide up to $725–735M, adj EPS…

AI-server order book unchanged since the 2026-05-28 print ($51.3B backlog, ~$60B FY27 AI-server guide) while price added 26.4% in four sessions to a $467.27 close on 2026-08-04 — a new high built on cohort beta and Micron-driven sentiment,…

Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating…

Deal-arb discount narrowed to 7.5%: RKLB closed $82.83 on 2026-08-07, $15.33 inside the collar's flat band, so the package still marks $54.00 against IRDM's $49.93. Forty days post-announcement there is still no Form S-4, no FCC docket and…

Freight-recovery leg unresolved between the $266.91 low of 2026-08-03 and the $276.28 pre-print close; the 2026-08-04 reclaim of the June floor came on 825,678 shares against a 1.11M 20-day average. DAT's 35-day forecast published…

Relief bounce off the broker-liability selloff stalled: LSTR closed $183.09 on 2026-08-07 after $181.62 on 08-04, below the 50-day at $205.13 and above a rising 200-day at $166.56. DAT dry van and flatbed have fallen two straight weeks to…

Custom-silicon ASIC royalty story intact, but the AI-semi theme is mid-correction — chips posted their worst month vs software on record (7/17) with money rotating into energy. Buying a falling sector with no confirmed higher low is the…

Record made 2026-08-04 ($190.46 close, $195.70 intraday) has held — 2026-08-07 closed $189.52 with no give-back. Second tuck-in in three weeks (JetStream, 2026-08-06, undisclosed). No Q1 FY27 webcast notice as of 2026-08-09, which argues…

The August 6 binary resolved on the numbers and broke on the tape: EPS $1.10 vs $0.49, guidance raised $250M, stock closed $26.54 from $30.11 and $27.90 on August 7. What is left to buy is a post-print reset into the September 16 Investor…

Q2 printed +51.7% revenue and a third FY26 guidance raise on 2026-08-06, then the stock lost 33.89% to $118.02 on 08-07 as management dated second-half growth at roughly 30%. The acceleration leg is over; what is left is a de-rated…

The 2026-08-04 breakout above the July band failed within three sessions — SNX closed $252.42 on 2026-08-07, back inside the $235.67–$255.70 range and under the 50-day. The move up came on Arista's print, not company news; Hyve's +117%…

Maturing AI-storage supercycle with sell-side still chasing: Wells Fargo upgrade to Overweight $1,100 (7/10) and Citi Street-high $1,240 (7/13). But the DRAM ETF is down ~30% and Seagate's Q4 FY26 print ~2026-07-22 is a binary about two…

Atera's order book turned the name: the 2026-08-06 beat-and-raise first sold to $45.60, then reversed to a record $52.03 close on 2026-08-07 (+14.10%, 5.43M shares) with the 16-analyst average target moving $41.54→$46.31 in two sessions.…

Silicon-photonics pivot re-rated the ADR ~3x, but the July blowoff to $28.96 round-tripped -26% to $21.25 in days while sell-side finally upgraded (Macquarie Outperform 2026-07-14) — late-stage distribution behaviour. The 2026-07-29 Q2…

The 29% bounce off the 2026-07-28 low stalled: WDC closed $527.22 on 2026-08-03, −3.23% on a day its sector rose 0.58%, back under a rising 50-day at $562.65. Consensus (~$3.69B / $3.31–$3.35) still sits above the company's own $3.65B…

Beat-and-raise LTL margin story the tape only half pays for: after Q2 adjusted OR 79.9% and an at-least-200bps full-year guide, price lost the $199–$201 shelf on 2026-08-03 at $197.01 and reclaimed it 2026-08-07 at $202.58 with no company…

Q2 delivered into the 2026-08-04 FCC policy gap: revenue $191.9M (+86% YoY), first non-GAAP profit at $0.06 vs $0.01 consensus, capacity sold out through mid-2027. But the Q3 EPS guide of $0.11–$0.26 tops out under the $0.28 consensus,…

Order cadence is intact — 2026-06-17, 07-09, 08-04 — but the 2026-08-04 spike to $109.89 has bled to $103.07 (2026-08-07 close) with no company disclosure since. The second distinct hyperscaler AI-ASIC order that the $130–150M FY2027 guide…

Grid/advanced-conductor supplier to data-center and utility power; backlog still ~+40% YoY (~$280M), but the tape broke after the 2026-05-28 beat-and-soft-guide and a late-June Russell removal piled on passive selling. Below the lost ~$40…

BTC→AI landlord whose operating build (>1 GW contracted, ~$31B backlog, 175 MW live) has decoupled from an equity that halved from $49.65 to a $25.79 low, now bouncing off the $25.56 April base into a binary FY26 print on 2026-07-27.…

Reclaim leg running straight into the binary: 2026-08-03 +8% to $63.52 on Meta's WhatsApp-over-BlueBird workshop, 2026-08-04 +10.69% to $70.31 into the launch. BlueBirds 11-13 flew 2026-08-05; the 2026-08-10 Q2 call is the test — $14.7M…

Nuclear-uranium theme MATURING and CCJ's structure has broken twice into improving news: mkt cap $44.79B (06-29) → ~$39.9B (07-25), ~$88, ~35% off the $135.24 high, absorbing a $17.5B federal AP1000 program and NJ's $24B plan. Barclays cut…

Thune reversed on 2026-08-03 and put a pre-recess CLARITY floor vote back on the calendar, but no cloture petition had been filed as of 2026-08-04 and Polymarket prices 2026 enactment near 27%. The company-guided stablecoin markdown still…

Float-royalty leg is finished; the stock now trades on Arc. Q2 (2026-08-05) printed $73.3B USDC circulation and $701.3M revenue vs $718.6M consensus, but FY26 other-revenue guidance doubled to $310–330M and Arc mainnet targets 2026-09-16…

Four sessions took CRWV from the 2026-07-29 low of $60.55 to a 2026-08-04 close of $91.90 (+51.1%), stalling just under a declining 50-day $93.13 and 200-day $94.35 on Piper's $151 initiation and a 360 MW Indonesia build — while the credit…

Event contracts now out-earn crypto ($156M vs $100M in Q2) and private venue marks are re-rating — Polymarket in talks above $20B on 8/4 against Kalshi's $22B. HOOD closed higher twice off the $85.30 low to $93.51, but the 50-day $97.28…

Broken gov-capital quantum leg, now publicly capitulated: seven-plus down weeks, an inverse-ETF complex up to +108%, and Cramer warning it off air on 2026-07-23. Washed out but not based, heading into a binary Q2 print (est. 2026-08-05 to…

Neocloud re-rate has fully round-tripped: $33.62 close 7/17, -42% in 30 days, late-May Microsoft breakout base surrendered. Contracts intact ($9.7B MSFT, prepaid tranches) but Q3 AI revenue was only $17.3M vs a $3.4B ARR ambition, and…

Two legs now: contractual indium phosphide supply ($87M reserved to 2031-12-31, agreed 2026-07-29) and a draft FCC ban on new Chinese transceiver models (Reuters, 2026-08-04). AAOI's 2026-08-06 print and $255–290M Q3 guide confirmed cohort…

Capex-discipline leg died at the 2026-07-29 print; the replacement is Meta Compute — one hire, one call quote, still no signed customer. The two-session rebound to $587.94 (2026-08-04) stalled under the 50-day on lighter volume, and…

Preferred-peg repair funded by coin sales and common issuance is the live leg: MSTR closed $97.65 on 2026-08-04, a second gain after the 2026-08-03 disposal 8-K, while STRC sits at $92.53 against a $100 stated amount. The 2026-08-10 weekly…

The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the…

Nuclear-microreactor narrative has stopped converting news into demand: a Truist Hold/$22 initiation (7/14) and a Virginia consortium announcement (7/17) landed inside four sessions and NNE still printed a fresh 52-week low at $15.78…

Three straight cohort-driven sessions carried OKLO from the 2026-07-29 close of $36.84 to $43.33 on 2026-08-04, with no Oklo release behind any of them. The 2026-08-07 Q2 call is the binary.

The $19.16–$19.83 shelf held eight sessions and PL gapped out of it on 8/4 to close $22.83, the highest since 7/21 — but both up days came on sector beta with no company news, on below-average volume. SpaceX's debut print beat on revenue…

Two unpriced agreements in six sessions — AT&T 07-27, Nasdaq Verafin 08-03 — carried QBTS back over the AT&T spike high on half the volume, but it still sits under a 50-day at $22.53. The 2026-08-06 pre-open print against a $4.03M…

Sector bid extended a second session on 2026-08-04 — QUBT $9.23, +26.4% from the 2026-07-29 close of $7.30 with no company news since 07-27 — but it was again the smallest gainer in its group and still sits under a $9.51 50-day line. The…

Quantum pure-play basket is in outright hype-cycle deflation: RGTI ~$14.19 (2026-07-17), -27% MoM, and the $14 shelf that held the May CHIPS-stake gap and the June executive-order pop has broken. Inverse quantum ETFs printing +108% and the…

Second up-day into tonight's print with nothing new disclosed: SMR closed $9.49 on 2026-08-04 (+5.33%), 25% above the 2026-07-29 base and still under a falling $9.90 50-day. Q2 consensus spans $1.0M (Zacks) to $8.80M (MarketBeat) on a…

Terafab (2026-08-06) put a number on the split: $16.8B first phase, and Musk's approximate guess allocates ~25% of output to Tesla Optimus versus ~75% to SpaceX — the listed entity co-funds compute it mostly does not receive. Energy is the…

Q2 (2026-08-05) missed both lines and rare earths contributed roughly $0.1M of $25.1M revenue, yet the tape made a higher low and closed 08-06 at $12.90, best since 07-14. The mine-to-magnet story now rests on the 2026-08-12 ASM scheme…

Peers raised 2026 guidance twice this week (TLN 08-05, CEG 08-06) and the complex still de-rated; VST fell 8.15% on 08-04 alongside NRG's -15.48% earnings break and closed 08-06 at $141.38, under the 07-29 flush low of $142.81. The 08-07…

Butterfly Embedded chip-licensing story got marquee validation — Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but…

Copper-to-optical interconnect narrative intact as a business (bookings into 2028, ~$1.9B NVDA stake) but the positioning trade is in distribution — ~35% off the 2026-06-02 ATH after correlated basket flushes. Week-of-7/21 semi rebound is…

Optical/AI-infrastructure demand is intact (Q1 Optical +36% YoY; Amazon/Meta/Nvidia deals) but the tape broke — a 43% drop off the 2026-06-30 ATH of $271.78 to ~$155. The 2026-07-28 Q2 print is the binary; two trading days out, nothing in…

Legacy crypto-financials name re-rating to AI-data-center landlord: Phase I ~200MW at the Helios campus was delivered to CoreWeave on 2026-07-06, turning the ~$4.5B/15-yr lease from promise into live contracted revenue while shares still…

Bitcoin-miner-to-AI-datacenter-landlord re-rate is now financed fact ($4.25B IG notes 6/4, ~$16.8B contracted backlog), but the momentum leg rolled from ~$127 to ~$105 as peers WULF/IREN captured the marquee Anthropic tenant deals (7/6)…

Post-liquidation base holding but not extending: four closes $99.81–$101.65 (2026-08-04 to 08-07) while volume decayed ~40% from the reversal day. Terafab's Grimes County site confirmation and SoftBank's $8.2B Intel gain add narrative…

Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing,…

The WFE/AI-memory capex trade that ran Lam +119% YTD into June has rolled into a group-wide correction — the worst month for chip stocks since 2008, memory momentum broken (Micron/SanDisk). The ~2026-07-29 FQ4 print is now the binary: it…

US critical-minerals-independence trade keeps getting rejected: a bullish 2026-07-20 defense-sourcing executive order failed to lift MP, which fell 7.5% on 07-24 to a fresh 52-week low ~$41 (~58% off the Oct-2025 high). Best-case policy…

July de-rating unresolved and now compounded by capex scrutiny — Alphabet's first cash-flow-negative quarter since 2004 and Intel's punished $20B capex plan raise the question of whether hyperscaler spend slows. Jensen's open-weight-AI…

June breakout fully round-tripped: ATH $386.46 (6/30) to $279.85 (7/17), now below the 50-DMA at $294.49. The tell is non-participation — TSMC raised capex to $60-64B and ASML guided up twice on 7/15-16, and ONTO closed the week at its…

The gamma-squeeze/index leg is over: PURR is -42% from its 6/1 high of $11.62 to $6.68 (7/17), through the $7.70 shelf, and now trades at roughly 0.78x the value of its 17.6M HYPE stack — a treasury premium that has flipped to a discount,…

The data-center re-rating already failed: QCOM spiked to a 52-week high of $259.92 on the ~2026-06-24 Investor Day $15B-by-2029 guide, then gave back ~34% in 17 sessions to $171.78 as Hold downgrades and Apple modem-attrition math…

BTC-to-AI-landlord re-rating is structurally intact — AMD $311M/50MW Rockdale lease, $33.2M Q1 data-center revenue, Citi reiterated Buy/PT $28 on 2026-07-08 — but the miner complex rolled over on a Q2 crypto rout and "fresh AI-pivot…

Defense-backlog re-fire interrupts the mid-July rollover: the 7/20 $17B NSSL Phase 3 Lane 1 qualification and 7/21 $266M suborbital award stabilized the tape after the 7/13 support break and Piper's 7/16 Neutral $83 cap. An unresolved…

Solar/BESS EBOS name re-rated as a 2nd-order AI-datacenter-power play on a record $758M Q1 backlog and the multi-GW ON.energy deal; price reclaimed the $10 pivot but consensus PT sits at spot (~$10.63 vs $10.02), so the confirmed…

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026,…

Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17)…

Q2 (7/16) beat every line and lifted FY26 growth guide above 40%, but the capex raise to $60–64B and a 2026-07-26 Samsung–Broadcom $200B foundry pact reopened the monopoly question. Theme cooled to maturing; price recovered to ~$415, still…

Conway extract/RTD/flavors platform inflecting capex-to-cash: Q1 (5/07) beat + record adj EBITDA + FCF-positive-H2 guide; the 6/30 debt-maturity extension cleared the refi wall. Stock re-rated to ~$9.50 near the $9.81 52-wk high. Q2…

Q2 (07-16) missed at $2.12 vs $2.25 and management cut the FY alumina outlook on Pinjarra refinery problems — five sell-side target cuts in nine sessions (BMO $55, JPM $52, WF $71), zero raises. The Hormuz premium is gone, the next…

BASX data-center cooling re-rating is intact but the setup for a fresh buyer today is poor: four days from a binary Q2 print (2026-07-30, inside blackout), KeyBanc just initiated at neutral (Sector Weight, 2026-07-23), ~55x forward with…

July's rotation-crown has slipped — Polymarket now gives Apple 20% odds of ending 2026 as the largest company (7/24) and semis are breaking out again (NVDA 7/23). The live narrative is the 'anti-CapEx AI trade' as Alphabet turns…

Second-leg breakout failed: after tagging a 52-week high $8.44 in early July, ABCL round-tripped to $5.31 (2026-07-24, -6.35%), losing the $6.79 shelf and $6.20 retest line, back at the June ~$5.09 base. The momentum edge is gone; what's…

CMS NTAP for ZEVASKYN granted 2026-08-04 plus a confirmed 2026-08-13 Q2 date have carried ABEO to within 0.7% of its $7.29 52-week high. The launch-ramp narrative is accelerating on reimbursement news, but the print is the binary:…

Single-asset UC biotech; the pivotal binary already fired (June 29 Phase 3 maintenance: ~50% Week-44 remission vs 10.4% placebo), the ~$920M raise cleared at $125, and 13 analysts caught it after the +36% gap. Now faded back to the…

Life-settlements franchise bolted the RWA-tokenization narrative (100+ policies on-chain, $224B TAM) onto a Q1 beat and a raised FY adj-EPS guide, but shares rejected the $12.44 high with a −7.3% sell-the-news day into a binary ~2026-08-06…

US-reschedule sentiment is spent for this name: the DEA Schedule-III hearing closed July 15 2026 with no ALJ timeline, and the economics accrue to US operators, not a Canadian LP. The Aug 5 Q1 FY2027 print is a guided transitional-year…

Oil-shock beta has decoupled: the Strait of Hormuz is physically shut yet WTI holds ~$71 on a rebuilt glut, while ProFrac sits in its 52-week-low neighborhood (last ~$4.90, 2026-07-09) over a loss-making frac core and ~$1.05B net debt. The…

June memory/HBM semicap re-rating that ran ACLS to a $193.78 high has broken; stock chopping ~$134 (−5.2% on 2026-07-24), ~31% off high, on flat FY2026 revenue. Forward path is now two binaries: the 2026-08-06 Q2 print and the…

Post-crash re-rating leg: the 2026-06-18 FY26 guide cut took ACN -17.9% in a day to a $118.15 low, then a $7.5B buyback (+62% YoY, must complete by 2026-08-31) plus named AI wins (Google Cloud, NATO, UniCredit) drove +24.8% in four…

Record-revenue franchise priced for terminal AI disruption: closed 2026-07-31 at $250.41, ~9.6x NTM earnings vs Microsoft 23.1x, 31% below the 52-week high, with a $25B buyback running. The bear narrative is fully mainstream and nothing…

Analog cyclical-trough plus the $1.5B Empower AI-power option fired and fully repriced in one week around the ~2026-05-20 Q2 print; ten weeks on, four more target raises (Cantor $550, Keybanc $525) are sell-side catch-up on a told story…

De-rated design-software compounder: Q1 FY27 revenue +18% to $1.934B and current RPO +18%, against a stock 23.8% under its $326.79 high. The $3.6B MaintainX close (2026-08-03) extends the franchise from CAD seats into asset operations; the…

The ADVA-merger margin-recovery turnaround — the whole reason for the ~$7→$20 re-rate — cracked on the 2026-07-22 preliminary Q2 miss (rev $280–282M below guide, non-GAAP operating margin ~3.5–4% vs a 5–9% target, GAAP loss, EPS collapsing…

Datacenter-power picks-and-shovels re-rating is now fully mainstream — Morgan Stanley initiated Overweight $421 (07-22) atop Wells $465 and Susquehanna $535 — yet the stock fell 12.65% on 07-02 and is sitting on its 200-day while analyst…

Frac-sand legacy pivoting to behind-the-meter gas power for AI data centers, but the story is DORMANT and the structure broken: shares fell from $16.73 (6/29) to an $11.96 close (7/24, -8.5%), losing the ~$15 base and $13 shelf on…

The +80%-off-March recovery re-rate has matured and rolled over: Morgan Stanley pulled its Overweight ('valuation call') on 2026-06-25, and price faded ~30% from the $100 high back onto the reclaimed 200-day near $70 while targets stayed…

AI-data-center gas-EPC theme still ACCELERATING (4.1+ GW gas backlog, $973.6M cash, zero debt), but AGX has round-tripped from the $805.75 ATH to $563, losing both the ~$675 breakout and ~$600 shelves. Mean reversion toward the pre-run…

Hospitality vertical-SaaS recovery has re-accelerated into its print: AGYS ran ~+18% to $108.98 (2026-07-10) off the June ~$92 base, clearing the two lowest analyst targets ($100/$110) ahead of a confirmed 2026-07-27 Q1 FY2027 binary that…

Semiconductor-IP royalty re-accel (Q1 variable royalties +67% YoY, FY26 guide raised to $91-95M) is fundamentally intact, but a $48.59 blowoff top (6/30) reversed ~29% and closed back below the ~$39 breakout shelf. Momentum leg is broken;…

AI-agent-security theme is accelerating, but AKAM's July 8 re-firing (+8–10% toward $126) has fully faded to ~$115, rolling back toward the June lows — a legacy-CDN-to-security/compute pivot that is NOT confirming the theme's momentum. The…

VOICE outcomes win (USRC trial stopped early, June 2026) de-risked Vafseo's dialysis-anemia case, but the tape bled to ~$1.22, only ~48% above the $0.82 low and still fading; the late-July/early-August Q2 print is the binary —…

Coverage-and-flow leg has crested: -25% from the 2026-06-30 all-time closing high of $32.23 to $24.13 on 2026-08-07, no new sell-side action since JPM's 2026-07-14 maintain at $33, and three insiders selling in July's post-lock-up window.…

AI rack-connectivity leader caught in a cohort-wide de-rate: down ~42% from the late-June $499 ATH as semis log their worst month versus software and the "is the AI trade cracking" question takes over. The $300 June recovery base is gone,…

The June AI data-center power-attach re-rate has flipped from being marked up to marked down: TD Cowen cut its target to $66 (2026-07-13) and Barclays downgraded to Equal-Weight at $48 (2026-07-20), the first target below the June range —…

Profitable-MA-disruptor narrative broke on 2026-07-08: a whistleblower suit from a former Chief Transformation Officer alleges the +88% adjusted-EBITDA inflection was manufactured by reclassifying opex as capex across FY2024-25. Shares…

June fuel-relief momentum trade failed at its 2026-07-21 binary: Q2 economic fuel spiked 85% YoY to $4.43/gal (no Hormuz relief), revenue missed at $4.065B, and Q3 guided to $0.00–$1.00 adj EPS vs $1.38 est. Sell-side now cutting targets…

Door-hardware compounder gapped +12.6% on 2026-07-23 after a Q2 beat (adj EPS $2.40 vs $2.22) and an FY26 guide raise to $8.85–9.00; durable legs are the electronic-access mix shift and an emerging data-center physical-security vertical…

Best-in-class oral TYK2 story sitting near 52-week highs (~$28) as the market waits on the Q3 2026 LUMUS Phase 2b lupus topline — the binary that either re-rates envudeucitinib into a multi-billion indication or caps it as a psoriasis-only…

Closed special situation: Arcline's $29.00 all-cash take-private (signed 2026-06-16, ~$272M, Q3-2026 close) hard-caps the stock. At $28.65 (2026-07-21) only a ~1.2% arb spread remains after the 2026-07-16 preliminary proxy — a frozen…

Ethanol-to-specialty/low-carbon pivot re-rated ~6x off $0.92, but both fuel catalysts — the June 45Z cash sale and the Russell index add — are spent, and price has round-tripped from the $6.11 July high to ~$4.64, losing the $5.10-$5.20…

WFE toll-collector on the AI-silicon buildout. June's +54% parabola — the most overbought reading in its history — corrected in July's semiconductor selloff that validated Burry's short. Now a pullback-to-base test: the June breakout base…

Edge-AI silicon small-cap re-rating on Roth Capital's 2026-07-14 Buy initiation at a Street-high $125 PT, which re-opens upside above the spent $70 Needham/UBS cluster. But the last confirmed tape is the 2026-06-05 -12% distribution day,…

A second anchor — the $1.5B Nvidia advanced-packaging/test partnership (2026-07-23) stacked on the 2026-06-16 TSMC 10-yr Arizona deal — is re-rating Amkor from single-customer Apple OSAT toward US AI back-end anchor. But every catalyst…

Single-asset binary: Phase 3 LUCIDITY topline for avexitide in post-bariatric hypoglycemia is guided for late August/early September 2026 (reaffirmed 2026-08-06), while the stock has run 54.9% in three months to within 5.7% of its 52-week…

Healthcare-staffing cyclical recovery, real but MATURING and now at the highs: ~$32.9 (2026-07-24), just off a fresh 52-wk high $36.27 (~+120% off $14.87). Truist's 2026-07-22 lift to a Street-high $40 Buy is the first target leading…

AWS +28% YoY (Q1, a 15-quarter high) keeps firming while the 2026-07-30 Q2 print lands days after Alphabet's best-ever quarter shed $294B on capex fear. Fundamentals accelerating, hyperscaler-capex sentiment rolling over — the print is the…

The July 14–17 Delaware bench trial closed with no verdict and no buyout; the quick-resolution crowd unwound and ANAB round-tripped from the low-$70s to ~$54 (Jul 24). The whole equity is now a dateless wait on a Chancery post-trial…

Professional-services roll-up re-rating: from a $16.00 IPO on 2025-12-17 to a $47.33 close on 2026-07-31, powered by the 2026-05-12 guidance raise to $980M–$1.0B FY2026 revenue. Price is discovered on a 10.90M-share float with a fifth to a…

Precision-psychiatry re-rate (~10x off $2.85) re-armed on 2026-07-13 — a successful FDA meeting cleared an additional ALTO-207 monotherapy Phase 3 in TRD, funded same-day by a $100M raise at $26.48. Narrative refreshed, but every data…

Post-parabola digestion. The Apr–May "second-order AI power-semi" re-rate (~3x to $54.34) is fully priced, above the $30.50 consensus PT with no fresh company catalyst in 11+ weeks; the 2026-07-15 pop was a newsletter-driven volume spike,…

AbbVie's signed all-cash takeout at $135.11 (announced 2026-06-23, ~$10.9B, ~49% premium to the $90.38 pre-bid close) caps the stock at the bid and killed the IL-13 momentum leg. What trades now is merger-arb carry into an expected H2-2026…

Bitcoin-treasury premium stays inverted: the July 20 buy was just 21 BTC at $63,221 (19,921 coins), accumulation has slowed to a trickle while mNAV sits at a discount and the $2.55B ATM dilutes BTC-per-share. TD Cowen's July 22 target cut…

Advanced-packaging pricing power is real — quotes raised 20%+ (2026-07-01), 2026 capex hiked to US$8.5B, CoWoS-equivalent capacity tripling to 25k wpm — but the tape topped at $45.51 the same day and sits ~15% lower inside a 13% semi…

Rumor confirmed and cashed: Eli Lilly is acquiring AtaiBeckley (announced 2026-07-16) for $6.75/share cash plus up to $2.50 CVR tied to BPL-003/VLS-01 milestones. Shares gapped to ~$7.20 and desks cut to Hold en masse — momentum is dead,…

AI-security re-rate off the 2026-06-15 TrojAI deal has stalled: ATEN churning ~$35 below the $37.36 ATH, momentum cooling as Mizuho lifts its target to $34 but stays Neutral — analyst catch-up, not fresh conviction. The 2026-08-05 Q2 print…

AI test-intensity picks-and-shovels leader, but the narrative is MATURING: back-to-back upstream capex raises (TSMC $60–64B, ASML €43–45B) failed to lift the tape, and the ADR sits ~20% off its 2026-06-25 record, shedding another 6% on…

Cash-return re-rating in a shrinking business: EV of US$27m against US$2.67bn cash, a US$400m buyback authorised 2026-07-28 (~15% of market cap) and a restated RMB1.5bn 2026 dividend floor drove a +40% run off the 2026-06-05 low of $16.53.…

Cyclical-bottom bounce off the $69.69 200-day (7/16 low $68.95) has firmed price into the low-mid $70s, but ATKR sits below its $78 50-day with the Street uniformly at Hold (0 Buy/3 Hold/0 Sell) into a binary 2026-08-04 Q3 print. A base…

Gold/copper producer basing $53–$76 under a broken ~$72 shelf after a ~45% fall from the $110 high. Q2 output slipped 8% QoQ — first sequential drop after a record Q1 — as gold cools to the low-$4,000s and sell-side keeps trimming (JPM to…

Aurora shipped its scale-readiness milestone — second-gen International LT trucks with the safety driver removed (2026-07-22) — and the tape sold it, breaking the ~$6.00 base to ~$5.83 into a confirmed 2026-07-29 Q2 print. Good news, no…

Take-private is done: AVNS holders approved the $25.00/share all-cash AIP buyout on 2026-07-22 (~99.75% of votes cast), all regulatory clearances in hand, close guided by 2026-07-27 with NYSE delisting on completion. Price is pinned to…

TAVR disruptor whose de-risking catalysts (CMS CED, first US patients, French ANSM clearance) are now exhausted; price faded ~11% off the ~$11.06 high back onto the in-the-money $250M ATM near $9. No 30-day data binary — PARADIGM readout…

Self-help turnaround at a leveraged lab-supply distributor is being repriced: the 2026-07-29 Q2 print put VWR Distribution & Services back to +1.7% organic from -4.8% in Q1, and FY2026 organic guidance was raised to -0.5%/+0.5%. Price…

Beat-and-raise fired 2026-07-08 — Q1 adj EPS $1.85 vs $1.69, FY27 guide lifted twice on Metal Coatings momentum — but the catalyst is now behind the stock, which sits at all-time highs (~$157), ~23x forward and above consensus, with Wells…

Parent-level distress in the courts: ~2026-06-26 60-day São Paulo shield plus Chapter 15 in SDNY, Fitch C / S&P default (2026-06-30); management skipping ~$177M July–Aug coupons and pushing an extrajudicial plan (5-yr extension, 100% PIK)…

Late-stage small-cap CPaaS squeeze: +360% YoY into the mid-$70s, ~5% below the $79.08 high, with Citizens ($86, 2026-07-20). Riley ($85) both lifting targets in July. A confirmed Q2 print on 2026-07-29 is a binary two trading days out —…

Q1 FY27 gave the pivot real numbers (QNX $72.3M vs the $60-64M guide, FY27 raised to $594-621M), but the parabola broke: after a $13.59 high the stock fell ~37% to ~$8.54 on a meme unwind plus insider selling. Narrative maturing, price…

Lemonis "Everything Home" roll-up keeps closing deals — Container Store now wholly owned (2026-07-08), TwoPonds folded in (2026-07-01) — but the tape has bled from $5.83 to ~$4.96 and sits on the $4.26 52-week low as shares balloon past…

Broken-growth AID-pump name idling into a binary Q2 print (~2026-07-28, ~2 days out): the number decides whether new patient starts re-accelerate or post a second straight sequential decline. Two clustered sell-side PT raises (Goldman $19,…

Rotation-passenger thesis is dead and the self-help turnaround hasn't ignited: BBWI made fresh relative lows near $19 into the 2026-07-12 Ulta launch, down ~42% over 12 months and below its 200-DMA while the tape holds up. Goldman cut to…

Tape flipped since early July: BBY broke to a fresh 52-week high $87.35 (~$85.41 on 2026-07-17, +27.6% YTD) on RGB-LED TV exclusivity plus an AI-PC/MacBook refresh cycle. But price sits ~8% above the $79.15 consensus target while Loop…

Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,…

On-site SOFC power for AI datacenters stays ACCELERATING and cluster-confirmed — Oaktree/IDF's $1.7B project financing (7/16) blunts the July supply-wall short thesis and JPM lifted its target to $346 (7/21) — but the ~2026-07-30 Q2 print…

The premium-to-book re-rating has unwound: BH ~$384 (Jul 17) sits back under the ~$401/Class B book line while CBRL rallied to $53.61 — the holdco is falling as its main asset rises, re-widening the discount. A $500M ATM with ~$485M…

De-rate reversal off the $7.48 Nov-CRL low has stalled near $14 after peaking ~$16 in early July; the opakalim epilepsy pivotal (RISE3) topline is unscheduled 2H-26, sell-side is turning cautious (BofA Underperform $11), and a dilution…

De-risking headlines (dual-primary HK listing approval, Apple Intelligence China clearance, mid-July) rallied the HK lines but the ADR kept bleeding — cap down to $37.21B (07-24) from mid-$40B in June. Structure rolled over below the $110…

Statin-for-inflammation leg broke on someone else's Phase 3: Novo's ZEUS missed MACE at HR 0.99 on 2026-07-31 despite lowering hsCRP, and BIOA fell 59.6% intraday. QUELL-CV's primary endpoint is hsCRP — the exact surrogate ZEUS just…

Post-miss +46% V-recovery has rolled over — ~$44 from a ~$48.75 June high, never retesting the $53.53 ATH. The tell: fresh $500M buyback authority funded by the June 19 €900M notes landed and the stock still faded. S&P cut the outlook to…

Post-Q2 re-rate on capital return: the 2026-08-04 print delivered adjusted EPS $2.54 (+15%) on revenue +8%, $3.7B repurchased and a raised $650M savings target, and ten firms lifted targets on 2026-08-05. But room nights are guided to…

The +80% Q1 turnaround re-rate round-tripped from the $6.57 high and stays broken: BLDP trades below the lost 20-EMA (~$5.00) and the $4.80 shelf in a catalyst vacuum until the 2026-08-12 Q2 print, with Susquehanna's 2026-07-10 cut to…

Busted vertical-SaaS name re-rating on cash return: the 2026-07-29 Q2 print showed +3.0% organic and an affirmed FY26 guide with upper-half commentary, against ~$850M of remaining buyback authorization and an 8.16 forward P/E. The move is…

Casual-dining margin-repair story re-rated violently on the 2026-08-05 Q2 print (adj EPS $0.39 vs $0.29, FY26 adj EPS guide lifted to $0.90–$1.00). The narrative is three days old and already gave back from $12.29 intraday to a $10.95…

Argentina disinflation/credit-recovery basket; BMA is the best-capitalized domestic vehicle. Sequential CPI is genuinely improving (3.4%→2.6%→2.1%→1.9% MoM, Mar–Jun 2026), but the tape has gone nowhere since the Oct-2025 midterm leg — ~$90…

The premium-to-NAV engine that funded BitMine's ETH ramp has closed: $11.35B market cap on the 2026-08-07 close against $11.3B of stated holdings on 2026-08-02. What is left is an ETH proxy at book with a $4B buyback (16.1M shares retired…

Still a merger-arb wrapper rather than an oncology stock: the object is a planned $44–48M pre-close cash dividend plus a 3.69% stub in the AATD base-editing NewCo. The 2026-08-07 10-Q re-documented it ($72.6M cash, 75% RIF), but price has…

The 2026-08-04 Q3 print resolved the binary against the margin case: adjusted EBITDA margin 13.7% vs the ~16% guide, and FY26 EBITDA cut to $275–295M from $315–335M even as the sales guide rose. Demand held, profitability did not. Price…

Post-ASMS instrument re-rate broke back toward the $64.54 high and added a second leg: semiconductor-metrology strength (orders +20% YoY) pulled Leerink to $70 and top targets to $65–70. But at ~$62 the name sits ~13% over its 50-DMA and…

Drive-thru coffee comps re-accelerating (Q1 +8.3%, FY guide raised) and the sell-side is now catching up — Stephens initiated Overweight $80, Morgan Stanley to $88 in mid-July. But June's run to ~$72 cooled to the mid-$60s, and the…

Legacy oiler U.S. Energy rebranded June 8 2026 into Big Sky Industrial, a helium + carbon-capture pivot at Montana's Kevin Dome. A five-year $285/MCF take-or-pay offtake and Q1-2026 FID anchor the story, but first cash flow is Q1 2027 and…

Both legs of the wrapper are now rolling over: WhiteFiber (WYFI, ~70.5% owned) de-rated from $38.50 to $27.57 as the June neocloud mania cooled, and BTBT slid to ~$1.50, a step above its $1.25 low. SOTP discount still ~49% (~$745.6M WYFI…

Spring miner-to-AI re-rate has fully unwound: BTDR lost the $15 shelf to $12.56 (2026-07-09) as AI-cloud ARR plateaued at ~$69M for a 2nd month. A signed-but-not-effective Tydal colocation lease (2026-06-29) and a $36M Nevada plant are the…

July's Hormuz flare re-armed the oil-geopolitical premium, but it has since drained — WTI slipped to the low $70s and the 2026-07-17 sanctions wind-down passed with no barrel shortage, a contained-conflict bid rather than a supply shock.…

Broken IPO that cleared its 2026-07-21 lockup without a supply flood but is grinding on the $4.665 all-time low with no bounce; Goldman cut its target to $7.75, and the undated $100M Galaxy verdict plus the ~2026-08-26 Q2 print are the…

Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M,…

Housing-distribution margin inflection in a 7.86M-share float: the 2026-07-13 Trex distribution award plus a 2026-08-04 Q2 beat (adj EPS $1.15 vs $0.40 est) carried BXC to a 52wk high at the 2026-08-07 close of $89.88 — above both targets…

CAN-2409 lung program promoted to pivotal on the 2026-06-30 AURORA Phase 3 launch, and sell-side keeps stacking (Stifel Buy $22 on 7/13, avg PT ~$20 vs high-single-digit spot) — but the June breakout to $11.36 round-tripped to ~$9.50 and…

Casual-dining re-rate got a genuine second leg: Citi's 2026-07-10 raise to a street-high $90 (Buy) on a rewards/app traffic-inflection thesis gapped shares 7% to all-time highs (~$86, 52wk high $86.66 on 2026-07-18). For the first time the…

Q1 re-rate is spent and the tape has gone flat — CAL has chopped a tight $11–$12.6 band near $11.78 (2026-07-24), ~19% below its pre-print level and under the lost low-$13s June shelf. Slow brand-mix-shift value name, not an accelerating…

Legacy-diner turnaround has handed off from numbers to leadership: David Deno (ex-Bloomin' Brands CEO) takes over 2026-08-10 with shares roughly doubled YTD and the 2026-08-07 close of $57.79 above every published target except Argus's…

Activist-driven re-rate on a cheap professional-services roll-up: Reference Equity's July 7 letter to halt buybacks and resume M&A drove a +9.3% pop, and the tape is +36% in 30 days straight into a July 29 earnings binary that confirms or…

Cash merger-arb in its final mechanical innings: shareholders adopted the $13.25 Knox Lane take-private on 2026-07-16 (~72% of shares for) and HSR is cleared, leaving only customary closing before delisting. Pennies of upside vs a residual…

Humanoid-robotics de-SPAC: Churchill XI merges with Agility Robotics (~$2.5B, Nvidia/Amazon-backed, re-lists as AGLT). Theme intact, but the tape is an RSI-98 filing-driven blow-off that has since gone quiet with no dated catalyst until…

Post-blowoff digestion is deepening: the ~4x data-center site-work roll-up has bled from a $96 high back to its $63 average analyst target, now below the $73 secondary price and the 50-DMA. Q1 organic +64% and an $854M backlog keep…

Second-order AI-server reseller whose ~37% recovery off the $97 low has stalled: a mid-July push to $144 round-tripped to $133 by 2026-07-17, right in the fairway of the ~$145 consensus target. The re-rate (JPM, MS $170, Citi $145) is…

2nd-order AI-power name — Q1 orders +97% YoY and a first-ever >$1B backlog (2026-04-28) feed the datacenter/electrification capex wave, and the closed Thermon merger doubled EBITDA. But price rolled over ~25% off the $101.24 ATH to $75.63,…

Analyst-confirmed profitability inflection (Q1'26 adj-EBITDA +$4.0M, +24% product rev) in a 25-year blood-safety grinder, but the 2.7x off the lows is largely spent and price sits near 52-week highs (~$3.00). The 2026-07-30 Q2 print is now…

Edge-AI IP momentum leg has broken: June's reclaim to within ~3% of the $51.60 high failed, and the mid-July AI-capex scare (Moonshot model) drove shares back through the ~$44 base to the mid-$30s. Sell-side still carries $48–$55 targets,…

The rescheduling binary CGC trades on came and went: the DEA hearing closed 2026-07-15 with no verdict, briefs due 2026-08-17 and the ALJ recommendation undated into H2 2026, likely litigated into 2027. Shares closed $0.89 on 2026-07-24,…

Busted-IPO fintech: operations accelerating (Q1 rev +25% to $647M, first GAAP profit, FY guide raised to $2.66–2.69B) but the stock trades ~19% below its $27 IPO and bases near post-IPO lows — a compressed multiple, not an accelerating…

The 1.6T WaveLogic demand cycle is intact at the order book, but the trade has broken: $627.00 (06-02) to ~$370 (07-18) is a ~41% de-rating, and the $455–$467 shelf that framed the prior read is gone. Multiple compression from 54x forward,…

The May earnings-miss squeeze has fully round-tripped to a dead tape in the mid-$30s, below the ~$36 gap base, with the retail-sentiment narrative spent. The sole live driver is the 2026-08-05 fiscal-Q3 print — guided to a sharp sequential…

Court-ordered 4.5-Star legal win (2026-06-10, +18.9%) is a spent binary; the $4.23 breakout is holding near $4.32 as Canaccord lifts its target to $5.50 (2026-07-21), but the confirmed August 5 Q2 print — carrying the promised FY guidance…

Picks-and-shovels delivery play on CNS gene therapy: ClearPoint's SmartFlow cannula and MRI navigation are the standard route to the brain for uniQure's AMT-130 Huntington's BLA (soft Q3-2026 window). The June re-rate held near $18.72…

AI-datacenter EMS picks-and-shovels story still fundamentally climbing after the 2026-04-27 Q1 crush (rev +53% to $4.05B, FY26 guide raised to $19B), but the tape broke ~21% off its $474 June high and heads into a binary 2026-07-27 Q2…

Pure-play SBS paperboard cycle inflection: two announced $60/ton price increases plus ~300kt of industry capacity out YTD took Q3 adjusted EBITDA guidance to $20–30M from negative $8M in Q2. But the 2026-08-07 close of $23.31 is a 52-week…

Hormuz war-risk re-escalation fired — the US-Iran MoU collapsed and tankers were struck 2026-07-19/20 — yet CMBT stalled near $15.7, ~11% under its $17.72 high, while broad VLCC spot bled ~40% off the late-June ~$470k/day peak. The equity…

Sell-side cluster finally formed — Citi Buy/$45 and Mizuho Outperform raised to $41 (both 2026-07-13) joining JPM's Overweight, plus first Mexico restaurant announced — but the ~2026-07-22 Q2 print is three days out and no weekly 20-EMA…

Takeover optionality cleared its first test: the 2026-07-29 Q2 beat (adj EPS $1.38 vs $1.11 est, organic +6%) and raised FY guide ($4.48–$4.60) removed the standalone-collapse case and carried price to $49.12, above every dated sell-side…

Terminal special situation, unchanged: Lilly's $38.00 cash plus up-to-$9.00 non-transferable CVR scheme became effective 2026-06-24, last Nasdaq print was 2026-06-23, and Form 15-12G is dated 2026-07-06. The only live development is…

Q2 FY26 (2026-07-23) beat on every line — net sales $216.2M +28.1%, EPS $0.82 vs ~$0.55, FY guide raised to $790–805M — and the stock still closed $62.25 on 2026-08-07, -25.9% from the post-print high. Beat-and-raise absorbed by sellers;…

Fee-reform catalyst landed: the 2026-07-13 Ninth Amended MSA cuts the base fee from 2.00% to 1.25% of ANA and caps 2027 base fees at $30M (est. $19–22M saving) — but nothing hits P&L before 2027-01-01. Price recovered ~$10.08 (2026-07-08)…

Now stretched into a binary ~2026-07-29 Q2 print ($4.0–4.2B guide) with an open NY AG antitrust probe.

Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry…

Distressed, highly-levered beauty turnaround (net debt ~$3.17B, ~3.3-3.4x) bouncing +23% off its ~$1.82 all-time low on the ~$400M Gucci license transition to Kering and cost-out. A de-lever story, but the ~Aug-19 Q4 print is the binary…

Deal-arb thesis is now spent: the $100M Apotex asset sale closed 2026-07-01 after a 99.84% shareholder vote on 2026-06-24, so the dated binary that drove the ~3.2x off $1.85 to a $7.36 high is consumed. What remains is a cash-rich clinical…

Hardware-to-platform crossover: Q2 2026 Platform revenue $85.0M (+5%) now exceeds Products $71.3M (-22%), and shares gapped +22.9% on 2026-08-05. The fuel was non-recurring — $20.3M IEEPA tariff refunds plus a $6.4M reserve release; the…

Elliott-driven turnaround at a beaten-down CRO: a ~$295M cost program plus 120–150bps margin expansion is re-rating the stock even with organic revenue still negative (-1.5% Q1), while Q1 proposals up high-single-digits YoY hint DSA…

Momentum leg is dead: the story crystallized into Vertex's $85.00/share all-cash takeout (announced 2026-07-06, ~$10B). Shares gapped to ~$83.50 and now trade as a merger-arb spread capped at $85 with ~$40 of air below on a break. Residual…

Turnaround re-rating still catching fresh fuel: analyst targets cluster up to $160 (BofA 2026-07-23, Seaport 2026-07-20) on North America DTC re-inflecting, lifting CROX to ~$135 within 4% of its all-time high at ~10x forward. Revenue is…

Aero-defense superalloy pricing cycle intact (three contracts at >30% hikes; Q4 op-income guide $205-210M, +37% YoY), but the July flush to $532 has been bought back to ~$603 straight into the 2026-07-30 Q4 print — now four sessions out…

Margin-inflection leg: Q2 FY26 (2026-08-06) delivered adj EPS $0.23 vs $0.07 consensus, a record 33.2% gross margin and an FY26 EPS guide of $0.85–$0.94 vs $0.72 est. Price closed 2026-08-07 at $14.35, the 52-week high and above three of…

Takeover-premium leg is dead: the 2026-07-06 Vista/Quinti gap is fully filled and the 2026-08-05 print cut FY26 contribution ex-TAC guidance to $1.034–1.058B from $1.175–1.198B, re-basing the standalone any bid would price. No board…

The 2026-08-06 Q2 update pushed the registrational PTCL interim from late 2026 to a Q1 2027 futility analysis that publishes no efficacy data, and set AD Phase 2 topline at Q3 2027 — the binary clock this name traded on is now empty until…

Legacy-networker AI re-rate intact and now at its binary: the $118–120 shelf held through July, price closed $121.43 on 2026-08-07 with RSI(14) at 78.4, and five sell-side target raises landed 07-22 → 08-06 (Citi $112→$139) ahead of the Q4…

Policy-relief leg stayed dead: the 2026-07-24 Jeffersonville HJT cell-plant opening — the reshoring narrative's first hard proof point — drew no bid, with the 2026-08-07 close at $15.91, 52.6% under the $33.58 adjusted high. The 2026-08-27…

Value-apparel turnaround is fundamentally accelerating — Q1 FY2026 comps +13.9%, a 21-month positive streak, a raised FY guide — but the 2026-06-02 print was the catalyst and it fired ~7-8 weeks ago. On an ~8.1M float with 10.5% short…

Legacy IT-services name being re-underwritten as an enterprise-AI deployment partner: 2026-07-29 Q2 lifted FY26 adj EPS guidance to $5.70–$5.82 and expanded margin 40bps while cutting the FY revenue band to $22.04–$22.35B. The re-rating is…

Post-exemption refining recovery is measurable — Q2 2026 adjusted EBITDA $209M vs $99M a year ago, refining margin $9.94/bbl vs $2.21 — but the tape has stopped paying: $31.15 close on 2026-08-07 is 21.9% under the $39.89 high, and…

The margin-inflection leg broke at its own catalyst: Q2 (2026-07-29) adjusted OR 95.9% vs 94.6% PY — second straight quarter of YoY deterioration — revenue $332.9M missed $340.4M, and Stephens cut its 23-day-old target to $54 on 07-31.…

Currency/payments spinoff re-rating on two legs: a US "Catalyst Series" banknote redesign (redesigned $10 late 2026, higher-denom print volume ~+90% vs 2025) plus a De La Rue + Antares authentication roll-up (SAT sales +51% YoY, FY sales…

June's $50M raise at $3.05 (16.4M sh) is already underwater: shares last $2.775 (2026-07-02), below the offering floor, with ~$50M shelf undrawn and soft Q2 guidance (rev $93–95M, adj. EBITDA still negative) into the 2026-08-10 print. A…

June's sell-side upgrade wave has exhausted and the first cut printed — Bernstein to Market Perform (PT $226, 2026-07-06) as the stock rolled over. AI-observability narrative intact but maturing; the $278.71 parabola round-tripped and the…

Definium re-accelerated off the June Phase 3 MDD win: a Wells Fargo initiation at $68 (7/27) and Piper's $75 (8/7) carried it to $46.14, 4.8% under the 52wk high. The leg being bought is DT120 as a multi-indication CNS franchise — and the…

The AI-server/auto power-content re-rate that carried DIOD to a ~$126 all-time high (June 18) has round-tripped: a double-top, an analyst downgrade, more insider selling and a sector-wide semi selloff pushed it to ~$96 by July 10, through…

Fusion pivot is the leg: the 2025-12-18 all-stock TAE Technologies merger (>$6B, ~50/50 fully diluted) is what's actually being bought, while the crypto-treasury leg was terminated 2026-08-07. The S-4 was still unfiled as of 2026-08-05,…

Deleveraging-and-refranchising turnaround with a now-dated catalyst: Q2 FY2026 prints 2026-08-06. Net leverage cut to ~5.5x from 6.7x, liquidity >$300M, but revenue still shrinks and ~23-29% of the float is short. The tradeable energy is a…

Fundamentals accelerated on the 2026-08-04 Q2 print (revenue +29% YoY, AI ARR +212%, RPO $894M, FY guide raised) and the stock fell 10.9% anyway. The $132 shelf flagged in the July coverage broke; the 2026-08-07 close is $124.15, -31.5%…

Legacy e-signature base being re-wrapped as AI "Intelligent Agreement Management" — IAM went 10.8%→12.6% of ARR in one quarter and is guided to ~18% by 2027-01-31, but total growth is still ~9%. Price has recovered to roughly the consensus…

The June–July re-rate has run into an empty calendar. The 2026-08-03 Q2 update pushed DT-168 FECD data to 2027 and re-cut RESTORE-FA to a 10-patient 12-week cohort with blood FXN protein as the primary efficacy endpoint, moving the next…

The pivot is now structural: the rail subsidiary was sold 2026-08-05 (related party — interim CFO owns 50% of the buyer), leaving an edge-colocation operator carrying a 2026-07-16 five-year 10 MW hyperscaler contract worth >$111M. The tape…

Census-recovery re-rate broke at the 2026-08-04 Q2 print: EPS beat ($4.02 vs $3.88) but FY26 EPS was only affirmed at a $14.65 midpoint vs $14.82 consensus, with H2 revenue-per-treatment guided slightly negative. Price -23.7% from the…

Legacy IT-services decliner being re-rated as an AI-centric pivot: AI-framed leadership change 2026-07-30, ElevenLabs and Primary partnerships inside ten days, FY27 non-GAAP EPS guide of $2.40–$2.90 affirmed against a $10.84 close.…

CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind — Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-$70s still under the 200-EMA and the confirmed July 30 Q2 print is…

Scarcity-premium narrative is dead: DXYZ closed $22.51 on 2026-07-28, below its last reported $24.56 NAV (2026-03-31), then bounced to $25.89 on 2026-08-07 as SPCX absorbed its 911.5M-share 2026-08-06 unlock. What trades now is a near-NAV…

Legacy IT-services base re-rating on an AI-delivery pivot: the 2026-07-29 Q2 beat (adj EPS $0.91 vs $0.82) plus a $115M Army DEVCOM AI award drove +16.3% on 2026-07-30. Revenue is still -1.3% YoY, RSI(14) hit 94.5 at the 2026-08-07 close…

June 11 was the last new clinical datapoint; what carried price to $60.46 on 2026-08-07 was the 8/5 Q2 print ($895.2M cash, runway into 2030, Fast Track) plus a same-week target cluster (Stifel $82, GS $80, Guggenheim cut to $78). Funded…

Lithium-recovery narrative is broken: Q4 FY26 revenue US$31M (−61% QoQ) at a realized US$921/dmt as legacy pricing rolled off, and Guangzhou carbonate hit a five-month low CNY 136,800/t on 2026-07-22. The new fact is a divergence — the ADR…

Post-collapse deleveraging read: Q3 FY26 (2026-08-07) beat at $271.7M revenue and $0.56 adj EPS vs $0.27, and the FY26 adj EPS guide went to $1.80–$1.90 — three months after a 57.8% one-day break on 2026-05-05. The leg being bought is a…

Post-Colfax orthopedic pure-play turnaround: LimaCorporate integration plus FCF-conversion recovery (43% in 2024 toward a 70–80% target) is the self-help story, but price has rolled over from $34 toward $27 while three brokers cut targets.…

IQ SST AI-data-center pivot (announced 2026-04-28) that drove a spring squeeze has stalled — stock de-rated ~16% in a month to ~$45 (2026-07-09), sell-side uniformly neutral with PTs on top of price (Susquehanna $45, 2026-07-10), and SST…

AI-native revenue is compounding ($160M in Q2, >11% of total) but the task-based book is running off faster — FY26 organic constant-currency growth was cut to 2.0%–3.0% on 2026-08-06, Q3 guided to ~1.7% YoY, and the stock closed $97.43,…

Take-private special situation: the board rejected Yellow Wood's $30 bid as too low, and mid-July sell-side PT raises (Canaccord $34, Wells Fargo $30) confirm a >$30 intrinsic read. But a month on no competing bid has surfaced, the theme…

European winter gas-security theme re-accelerating; Equinor, the swing Norwegian pipeline supplier, held ~$40 through a Q2 double-miss on a $1.125B buyback bid. But at ~$40.31 (2026-07-24) it trades above the entire sell-side PT range (avg…

Post-crash story reset: 2026-07-13 updated ERAS-0015 Phase 1 data (57% uORR at 32 mg in 2L+ KRAS G12X pancreatic, n=7) plus 2027 pivotal plans, immediately monetised via a 31,428,572-share offering at $17.50 on 2026-07-14. Funded, but the…

Resolved and off the tape: ARCHIMED closed its take-private of Esperion on 2026-07-13 at $3.16 cash plus a non-tradeable CVR of up to $100M aggregate, and the common stock ceased trading and delisted the same day. Last listed close was…

Smadex AI-DSP re-rate broke to a new 52-week high of $13.48 with no dated company news since 2026-07-12 — an anticipatory leg into the 2026-08-10 Q2 print, the binary on whether Q1's +204% ATS growth and ~22% EBIT margin held.…

The late-June retail bounce has fully unwound — EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which…

Legacy expense-SaaS pivot re-rated on the 2026-08-06 Q2 print: revenue $33.9M beat $33.688M, paid-member decline halved to -2% YoY, FY26 FCF guide doubled to $12M-$14M, ~7% of shares retired, and New Expensify ARR from net-new customers…

Legacy campus-networking name re-rating ~+140% off Feb lows on the Platform ONE / Agent ONE AI-NetOps story plus SaaS ARR +29% YoY; theme still ACCELERATING but spot ($33.71, 07-10) has run through consensus PT $29.06 into the June bull…

Freshly de-SPAC'd solid-state battery name has fully unwound its debut mania — down ~78% from the $25.33 ATH to ~$5.67, breaking clean through the former $9.26 floor into a fresh 52-week low at $4.24. Cantor's $18 target now sits ~217%…

Activist-plus-new-CEO turnaround has stopped accelerating and started digesting: after the +30% run off Garden's $40.6 buy, price has chopped $50–54 for three weeks while sell-side targets climbed past spot (Goldman $61 on 7/10, Barclays…

Street targets re-rated up to the price rather than the reverse: average PT $22.83 across 8 analysts vs the 2026-08-07 close of $20.43, after B. Riley $13→$32 (6/29) and UBS $22→$27 (7/14). The AI-power bid still works (7/30 Microsoft…

Design incumbent re-rated as an AI winner (BofA Buy, $30 PT, 7/7) rather than an AI casualty, yet the stock churns below its 100/200-day moving averages with heavy short interest into its first public earnings print on 8/5 — that print,…

Legacy-CCaaS AI pivot staged a sharp V-recovery: +29% off the $19.70 June swing low to $25.42, reclaiming the broken $22 shelf on a 2026-06-23 next-gen Voice AI Agents launch and an AI-first leadership overhaul. Now pressing the $26.26…

AI-manufacturing re-acceleration: the 2026-07-09 Cerebras CS-3 production expansion is the first company-specific bid since the S&P-inclusion +6% pop round-tripped to ~$147, refreshing the data-center power/EMS narrative into the ~07-29 Q1…

Narrative and price have fully decoupled: FLY stacked a $144M CLPS award, a Moon BASE seat and a $13M Mars subcontract into a -47% drawdown, falling 9.6% on 7/16 on the awards headline itself. At $19.27 vs a $45 IPO price and 31% below the…

Optical cluster re-accelerated in July (AAOI +390% YTD, LITE +138%, COHR +107%) while Fabrinet sits ~$478, +0.7% YTD and ~36% under its $748.89 high. Revenue compounds at +30% but the tape has decoupled from its own theme — a…

Legacy watch/accessories brand whose margin-first turnaround is showing in the numbers: Q1 2026 swung to $12.0M operating income from a $(6.7)M loss on net sales of $224.8M, and the FY2026 guide (-4% to -6% sales, 3-5% adjusted operating…

Payments roll-up at ~$50, a hair above its $46.26 52-week low set on a 2026 guide-down. The Global Blue tax-free-shopping integration ("Shift4 One," launched 2026-07-14) is the transformation leg, but the 2026-07-30 Q2 print is the binary…

Second secondary in five weeks — ~43.6M shares at $49 on July 2, now including company primary dilution — confirms the recurring-supply pattern and dragged the stock from its $65.56 June-4 ATH back to the offering line. The…

Tariff-driven HRC steel prices at multi-year highs powered record FY2026 (EPS $2.76, sales +46%); FRD hit an all-time-high close $37.42 on 2026-06-18 and was flagged overbought the same day. The narrative is maturing and priced near the…

The capitulation-to-re-rate leg is broken: FSLR closed 2026-07-31 at $211.03 versus a May high of $313.75, under both the 50-DMA ($245.17) and 200-DMA ($234.23). A Q2 beat on 2026-07-30 (EPS $3.92 vs $2.86) bought two sessions and drew…

Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited…

Agentic-operations pivot is compounding in the segment data — Advanced Technology Solutions +24.1% to $363M, FY guide raised to at least 25% on 2026-08-06 — but the 73% legacy book grew 1.9% and caps total growth near 7%. Shares fell ~3%…

Take-private arb in its endgame: DEFM14A filed 2026-07-06, vote 2026-08-03, HSR expired 2026-06-22. Closed $9.44 on 2026-07-31 vs the $9.50 cash price — ~0.6% gross left against a ~37% break tail to the unaffected $5.93. Only offshore…

Alternatives-manager re-rate stalled — GCMG printed a new $14.38 high on the 2026-07-13 Piper upgrade, then reversed ~15% to a $12.20 close into the 2026-08-06 Q2 binary. The AI-datacenter infra/private-credit fundraising thesis is intact…

The operating turnaround is real but priced, and its one asymmetric leg — the activist proxy fight — lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the…

June drawdown fully retraced — $23.01 close (2026-06-22) to $27.63 (2026-07-29), still short of the $27.76 shelf from 2026-06-01 — and it happened on no company news. The now-confirmed 2026-08-06 Q1 FY27 print is the first quarter with…

Sports-data toll-booth under the prediction-market boom, but the boom arrived and the toll didn't: Kalshi/Polymarket cleared $50B+ of World Cup volume (Coindesk, 2026-07-14) while GENI slid $6.43 → $6.30 and printed $5.98 intraday July 17.…

Post-launch broken-momentum hematology name: RYTELO 2L lower-risk MDS ramp is real but decelerating ($51.8M Q1 net rev, +31% YoY) while price holds near its $1.04 52-week low, below every major MA. The only live re-rate is the…

Mature-node foundry re-rating into a silicon-photonics/quantum-foundry story; partnership cadence still compounding (SEALSQ PQC MoU 2026-07-08). But a fresh entry now buys above the ~$79.72 consensus target, near the $92.55 52w high,…

Argentina disinflation is still working — June CPI printed 1.9% MoM on Jul 14, an improvement on May's 2.1% — but the ADR faded the good print, dropping ~7% on the week to ~$50 and losing both the $51.07 50-day and the $52.86 200-day.…

ZEUS (ziltivekimab, MACE HR 0.99) failed on 2026-07-31 and took GLUE −27.16% to $16.52, its worst session on record, because the hsCRP-to-outcomes link under MRT-8102's ASCVD story is exactly what ZEUS could not demonstrate. Platform,…

Premium-golf consumable franchise (Titleist Pro V1) that ran to a $119.65 all-time high on a defensive-quality rotation, then bled ~11% of the mania premium back to the ~$104–105 June breakout shelf ($104.66 on 2026-07-24). The 2026-08-06…

Q2 2026 binary resolved bearishly — Alphabet sold its own print (dropped with Tesla/Intel, 2026-07-25) into a megacap-AI cohort rotating toward saturation ($800B tech selloff 07-24, capital fleeing to cash-flow value). Gemini's frontier…

AI-native restructuring re-rate — up to 400 job cuts, FY26 EBITDA guide raised to $75–80M — plus a low-float, Russell-inclusion squeeze that popped GRPN +10% on 2026-07-16. But Q1 billings fell 1% YoY and sell-side sits at Sell: a maturing…

Sell-side is re-rating GSHD ahead of the tape: five price-target raises in eight days (Piper $52→$72, Cantor $76, UBS $70, JPM $60, RBC $55) against a stock still at $54.28 and -49% YoY. The 2026-07-22 Q2 print is the binary that decides…

US trade-remedy leg: the 2026-08-03 USITC affirmative vote forces AD/CVD orders on Australian and Norwegian silicon metal, on top of Angola/Laos orders live since 2026-03-17. Q2 (2026-08-04) delivered the sequential recovery — $13.1M adj…

Legacy B2B data business attempting to re-rate as an AI go-to-market platform. Q2 (2026-08-05) beat and raised on 1.2% revenue growth, 89% NRR and a $650.5M goodwill impairment; the stock ran ~14% in two sessions to $4.18 (RSI 76.9), above…

Turbo cash-cow re-rated (~8–9x → ~18x) on a datacenter/industrial oil-free cooling narrative; the parabolic Feb→June leg (~$20→$36) is spent, shares faded ~11% to the 50-day near $32.30, and the ~late-July Q2 print is the first chance to…

Vertical-SaaS insurance compounder de-rated ~52% from its $272 high; the 2026-06-04 Q3 beat-and-raise (rev +27%, ARR $1.147B) was sold and price sits in a broken structure far below every analyst PT ($180–258). The enterprise-software AI…

The July stall resolved upward: HAE broke its $77–80 July range to close $85.54 on 2026-07-31, 2% under the 52-week high, on a BofA target raise to $93 citing peer multiples rather than new data. The 2026-08-06 Q1 FY2027 print is three…

The 2026-07-08 double beat was sold — closed $25.18, -10.2% — because margins compressed (GM 46.0%, -110bp; adj EPS $0.17 vs $0.41). The live leg is now deleveraging: net leverage 3.48x from 3.87x, debt $716.1M from $871.0M, FY27 FCF…

Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a 10.3M-share secondary at $4.85. Both covering shops cut targets in July while holding Buy. No…

GLP-1 reaccel gets marked to market on 2026-08-10: guide $680-700M (+25-28%) vs Q1's +4%, street at $698.9M. Since the last note the FTC/CA/UT sued (2026-07-29, N.D. Cal.), BofA cut $37 to $30, and Amazon ($50/mo Medicare GLP-1,…

BTC-miner→AI-compute re-rating has its first blue-chip proof — BUZZ HPC's $220M Bell/Cohere sovereign-AI GPU deal (~$70M ARR) on top of $35M contracted ARR — but the stock stalled ~$3.79 below its early-June highs as BTC bled ~45-50% off…

Transformational Steelcase merger made HNI the #1 North American office-furniture maker at ~$5.8B revenue, but the tape is dead near $40 versus ~$70 analyst targets — a show-me integration grind, not an accelerating narrative. The…

Margin re-rate, three days old: Q2 gross margin 48.4% (+800bps) and a four-way FY2026 guidance raise on 2026-08-05 drove a ~39% single-session repricing. Price at $5.46 is a 52-week high, RSI 83.3, and above both $5 targets raised in…

The housing-bill leg is spent — the Act auto-enacted 2026-07-11 and nothing dated has replaced it — yet HOV has re-rated to $137.78 (2026-08-07), 11.8% off the $156.16 high, on no company news. The confirmed 2026-08-20 Q3 print (quarter…

The Hormuz premium round-tripped in the barrel — WTI $69.23 on 2026-06-25 after the 2026-06-18 MOU — yet HPK held its June shelf and closed $7.20 on 2026-08-07 with WTI back at $78.18. What remains is a cash-flow and deleveraging read on…

Commercial ophthalmology special situation trading on one number: whether the guided Q2 ramp ($71–81M vs $44.2M Q1) prints ~2026-08-11. A ~40% recovery off the May low into ASRS clinical data and a fresh BTIG $63 reiteration has front-run…

Freight-cycle recovery has a stronger structural leg than the rate data alone implied — regulatory driver purge (~194k CDLs, ELP enforcement) plus spot above contract for the first time since 2021. But HTLD is unprofitable, all six…

No base, no scheduled company event before UNBOUND on 2026-09-16.

Med-device turnaround re-rating is now fully banked into Hold-grade targets: BMO initiated Market Perform $19 (Jul 9) and Citi raised to Neutral $19 (Jul 8), both landing on the tape (~$18.76). The distressed-to-fair leg is done; only…

Memory-capex WFE subsystem re-rating broke on the 2026-08-03 Q2 print: revenue $294.8M missed $300.2M consensus, the $78 June shelf failed, and the 2026-08-07 close was $68.32 against a $112.28 high. Q3 guidance still beats ($315–345M vs…

M&A leg is dead — no SiriusXM headline since the 2026-05-29 NYT "stalled" report and the April spike fully round-tripped ($6.33 high → $3.86 on 2026-08-07, -39%). What is left is a binary: Q2 print 2026-08-10 after the close is the first…

Post-Parkinson's-failure microcap, now a single-asset PAH story (IKT-001 imatinib prodrug). IMPROVE-PAH Phase 3 only began enrolling 2026-04-07, so topline is 2027-2028 and there is no near-term binary. Stock ~$2.23 trades near its ~$200M+…

Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap…

Dilution overhang answered with debt: the 2026-07-16 Oxford amendment lifted the facility to $500.0M and funded $100.0M immediately, leaving the ~14.67M share count intact but the balance sheet levered into a nine-month wait for the…

Automotive ADAS-silicon design-win story keeps improving on paper ($7.4B backlog, $25M radar order, ams OSRAM sensor buy) while the tape stays broken below the ~$4.00 50-day MA; TD Cowen's 2026-07-13 lift to a $4.50 Hold is a thaw, not a…

The $39.49 tape is a frozen June 8 last-trade, not a live market — a ~3,600% blow-off from ~$1 on a $3M AI 'used-phone agent' deal, halted under Nasdaq T12 ever since while the board probes its own trading. Seven weeks on, still no…

Post-sanctions PACE turnaround still delivering (FY2026 adj-EBITDA guide $85–90M, census ~8,050 +6.9% YoY), but the tape shifted: a $12.11 52-wk high failed back into range ($11.18 close 2026-08-07), and the 2026-07-31 S-3 registered…

AI training-data pure-play with a still-accelerating fundamental story (Q1 rev +54%, 40%+ FY26 guide reaffirmed 06-17) but a fully broken chart: ~-51% from the June $125.14 ATH to ~$61, with the CEO filing a fresh 200k-share sale on 07-16…

Agentic-AI attach on a compliance-locked professional-firm base: Celeste launched 2026-07-15, Q4 FY26 (2026-08-04) beat with cloud ARR $495.7M +29% and 123% NRR, three targets raised 2026-08-05. But the FY27 revenue guide $656.5–660.5M…

Quality-defensive re-rating (~+39% YTD, ~$122) is maturing: Q2 net sales grew just 2% to $341M with anchor license Lacoste -19%, yet Canaccord chased its target to $141 (2026-07-23) as sell-side catches up to decelerating growth. Full Q2…

US critical-minerals sovereignty name whose funding overhang cleared the ugly way: a 2026-07-08 US$50M ADS raise priced at $21.98, ~22% below the ~$28 pre-deal level, resetting the stock to $22.94 near its $21.66 52-week low. Pre-revenue,…

Long-form streaming growth is broken in the reported numbers — Q1 2026 revenue -13% YoY and operating income flipped to a RMB228.4m loss — so what is left to buy is the micro-drama/overseas/AI-cost pivot, which has no disclosed revenue…

Special-situation biotech, not momentum: the 2026 Linzess pricing-restructure re-rate faded to the low-$3s, then bounced ~30% to a $4.65 close July 8 on M&A speculation with no confirmed bid, since fading to ~$4.21. The Aug 6 Q2 print is…

The equity is now a deal instrument: KKR's $127 all-cash agreement, signed 2026-08-03, leaves $1.73 of headline consideration above the 2026-08-07 close of $125.27, while a break returns it toward the $96–$110 pre-leak analyst zone.…

Single-asset MASH binary: lanifibranor's NATiV3 Phase 3 topline (Q4 2026) is the whole equity. The June 2 refinancing cleared the funding overhang (runway into early Q1 2028) and Cantor initiated Overweight July 17. Stock coils on the…

June's move was a float mechanic — Russell Microcap inclusion (effective 2026-06-30) into a 40%-short float drove $8.92 to $18.13, and it is unwinding ($14.98 on 2026-07-17, -7.76%). SSS is genuinely inflecting (-6.7% → -3.8%), but price…

Both binaries this stock coiled around have fired and are spent: JADE101's clean Phase 1 (2026-06-01, ~70% IgA reduction, q12w dosing) and Vera's TRUTAKNA accelerated approval (2026-07-07), which validated the APRIL/BAFF mechanism but put…

Fuel-reversion bull leg broke: Brent re-spiked to ~$86 (Jul 17) on renewed Mideast conflict, reversing the sub-$73 tailwind the whole trade needed. Raymond James (Jul 6) cut to Underperform flagging a Chapter 11 that wipes equity; $9.3B…

eVTOL cert story still advancing (FAA TIA testing, 2026 Dubai target) but the trade rolled over: ~$8 testing support, down ~33% since June 1, recovery base gone, CFO sold ~half his stake June 8, consolidation coverage marks sentiment…

Genuine FY2026 turnaround (loss→$3.6M net, record $166M rev) plus a +20–22% Q1 guide drove a +36% circuit-breaker gap on 2026-06-15. Six weeks on the catalyst is spent, the only new item is a 2026-07-21 board-chair succession, and RSI-88.6…

Section 232 aluminum supply-shock (50% duty through 2027) plus a Q1 earnings inflection already repriced KALU ~+175% YoY to a $195 high; the move is MATURING toward SATURATED with price at/above every published target. The estimated…

Closed takeout, not a security: Chiesi's $27.00/share all-cash acquisition of KalVista completed 2026-06-11, shares delisted from Nasdaq with deregistration (POS AM, Form 25, Form 15) underway. No spread, no momentum leg, no listed share…

Founder-led fleet-telematics compounder: Q1 FY2027 (2026-07-15) delivered a record 142,472 net Cartrack adds (+70% YoY) and +22% group revenue, but the stock had already run ~22% into a fresh 1-year high near $60 and prints overbought. The…

China AI-compute capacity story is intact on fundamentals — AI gross billing +90% YoY and past half of public-cloud revenue in Q1 (reported 2026-05-27) — but the price leg broke: -32.3% from the $18.21 high with RSI(14) back at 70.0. The…

Former Bitfarms miner→AI/HPC-datacenter pivot has rolled over: June's push to ~$6.14 into Citizens' $10 initiation retraced to a ~$4.975 ref by 07-06, losing the $5.00 convert shelf and drifting toward the $4.00–4.20 base. Still zero…

Deep-value staffing name three years into a specialty-vertical pivot (Europe sold to Gi Group, Motion Recruitment bought), but the tape is dead and the theme engine keeps re-labeling it with no anchoring headline — nothing is accelerating…

Cyclical staffing recovery is fully printed — Q1 returned to YoY growth, Q2 guided +~4% — but price ran ~24% in three weeks to a fresh all-time high near $58.6, ~38% above the $42.33 consensus PT, into the confirmed 2026-07-27 Q2 print. A…

Process-control monopoly (~58% share, ~7.5x nearest rival) with an accelerating custom-silicon narrative, sold down in the worst semi month since 2008. Six analyst PT raises in eleven days — but the July cluster ($255–274) sits well below…

Distressed post-IPO childcare name has retraced ~180% off its $1.75 spring low to $4.93 as growth shifts to B2B/employer care and before-after-school (Champions +17% YoY), while the core ECE business still shrinks (−3% enrollment). The ~13…

Freight cycle has physically inflected — tender rejections 17.2%, spot above contract for the first time since 2021 — but the tape stalled at ~$76.68 versus a $86.63 average target. The whole trade now compresses into the 2026-07-22 Q2…

ABC-platform redemption arc: after the 2022 DAZZLE wet-AMD miss took KOD to $4.60, back-to-back positive Phase 3 diabetic-retinopathy readouts (GLOW1, GLOW2) re-rated it ~9x. The September 2026 DAYBREAK wet-AMD topline is the binary —…

Pension-reversion fat pitch fired and is spent; the re-rate has fully unwound from the $14.87 May high to ~$7.78, losing the $9 June shelf and printing a $4.94 52-week low. A July 1 resale shelf of up to ~39.46M shares and a June 29 Sell…

Jubilee ramping toward ~90,000 bopd gross (J76 online, J77/J50 imminent) with GTA LNG volumes climbing. Highest-beta E&P expression bounced ~15% off the $2.00 June low; re-accelerating but still a ~$2.30, 'CCC'-rated, most-levered…

Tariff-refund windfall re-rating: a $25.8M IEEPA refund and a dividend raise to $0.47 drove a 15.2% post-print gap to a 52-week high $47.09 close on 2026-08-07 at RSI 86.9. The company's own Q3 guide (GM 35–37%, adj EBITDA margin 9–11%)…

Squeeze leg has stalled: Morgan Stanley's 2026-07-06 Underweight/$15 reinit broke the one-way upgrade cluster and knocked the stock -5.9% on 07-08. Price ~$17.18 still holds above the 50- and 200-day, but with the sell-side now two-sided…

The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A…

Klaviyo beat Q1 2026 (rev +28%) yet gapped -32% on a light FY26 guide (~$14–22M below consensus), a CFO exit, and visible deceleration (23% FY guide); shares sit near 52-week lows below the 200-day into a binary Aug 5 Q2 print.…

US critical-minerals-sovereignty policy re-warming (Pentagon's $725M Energy Fuels stake, the Intel/US Steel government-equity template), but the lithium-price recovery leg is cold — carbonate rolling over keeps LAC pinned to its $4.50…

The 2026 lithium-recovery narrative has broken: CATL's ~46ktpa Jianxiawo mine restarted 2026-06-29, pulling the supply-discipline leg out from under the rally. China carbonate fell to a ~4-month-low CNY 151,000/t and LAR sliced its $7…

Single-asset schizophrenia story re-rating on the 2026-07-22 pull-forward of NOVA-2 Phase 3 topline to H1 2027 plus a $150M crossover round at $34.94 on 2026-07-28. Price closed $48.00 on 2026-08-07 — above every published target ($45 HCW,…

In-vivo CAR-T re-rate has matured into digestion: EHA (6/13) confirmed LB2501's 100% ORR and clean durability, but the 6/17 $226M raise at $29.35 capped the leg and JPM's 7/13 Neutral $35 reinstatement caps the Street. No fresh catalyst…

Legislative-spike homebuilder fading into rising rates: LGIH gave back over half its 2026-06-24 ROAD-to-Housing gap, closing $58.52 on 2026-07-17 as ~6.65% mortgage rates dragged the whole builder cohort lower. Q2 closings grew +8.8% YoY,…

AI-datacenter MEP/HVAC pick-and-shovel story still improving on fundamentals (record $5.38B backlog, FY guide raised to $4.1–4.3B), but the tape has decoupled: ~33% off the $102 May close high, LGN sliced the $76 breakout shelf and rolled…

Contested insurtech IPO reclaimed its $19 price in a late-June ~28% rip and has held it into a fresh JPM Overweight (PT $23, 2026-07-13). But the reclaim runs into the 2026-07-27 final lock-up and an unresolved upfront-accounting short…

Insider-cluster leg has already paid: Malone/Fries/Nair bought the post-distribution $4.98 June base, and the common is $7.34 — ~47% higher in under a month. July brought Citi's downgrade to Neutral (PT $8) and a Barclays Underweight at…

Post-catalyst drift: the $500M preferred special dividend and the June Malone/Nair insider cluster already drove a ~70% run off $4.76 to ~$8.30, and the tape has stalled at $7.33. Citi cut to Neutral 2026-07-10 with a $8 target already…

Sell-side is converging on the sidelines right at resistance — Piper (Neutral, 2026-07-15), Morgan Stanley (cut to Equal-Weight 2026-07-08, $75) and KBW ($48 Underperform) all stepped back — while LMND stays boxed between the $50 neckline…

Legacy-risk-transfer re-rating: the 2026-07-30 Talcott deal cedes ~$5.8B of GUL statutory reserves for ~$200M all-in statutory capital, alongside a Q2 adjusted EPS beat at $2.24 vs $1.96. But the information is out, price sits 2.1% under…

Q1 FY27 (2026-06-11) beat in a shrinking furniture category, but the tape refused the news and no volume-confirmed reclaim has fired five weeks on. With ~27–31% short float and clustered June insider buys, the only live edge is a squeeze…

All-cash takeout has closed the story. ANV Group's $3.15 tender for Open Lending went live 2026-06-29 with a 2026-07-27 initial expiry; the equity is pinned to the deal price with no momentum leg — only a thin arb spread against…

Single-asset FA binary: nomlabofusp's rolling BLA for accelerated approval is live, but the 2026-06-29 open-label data carried an anaphylaxis signal (10 of 43 patients, ~23%) that turned the filing into a ~17% selloff. Shares drift near…

The June 30 NASA Moon BASE award ($148.3M Nova-C) bought exactly one green session before the stock broke: seven straight down days into 2026-07-13 for -24.5%, -36.5% on the month, $13.80 on 2026-07-18 versus a $38.55 May high. A live…

AI-reset narrative — a busted online legal-forms IPO repositioning as an AI-enabled SMB subscription platform (Anthropic partner, AI "digital mailroom") — drove a +29% 30-day rip into July. But it's stretched into the 2026-08-05 Q2 print,…

Morgan Stanley broke the all-Hold wall on 2026-07-06, resuming at Overweight with a $30 target and a $3 EPS-power call vs ~$2 consensus — the first real upgrade catalyst since the Q1 beat. But price faded the note ($23.99 → $22.64 by…

Deli prepared-foods roll-up keeps compounding — Q1 FY2027 (2026-06-08) revenue +49.7% YoY — but management top-ticked the 52-week high with a $100M raise at $18.00 (2026-06-30): ~14% dilution, momentum reset, theme cooling to maturing. No…

Cyclical staffing earnings inflection: Q2 beat (adj EPS $0.99 vs $0.95; rev $4.86B vs $4.72B) plus an above-street Q3 guide ($0.96–1.06 vs $0.88) drove a 35% short-squeeze spike to ~$52.77 on 2026-07-16. The binary catalyst has already…

AI/HPC power-buildout re-rate is the leg being bought — the 2026-07-09 HIF deal adds up to 2 GW in Texas, lifting potential capacity toward ~4.8 GW — but the golden-cross base fully round-tripped to ~$11.4 as analysts cut across the board…

Post-divestiture Mativ is being repriced as a self-help deleveraging story: the 2026-08-05 Q2 print delivered record adj EBITDA of $75.0M at a 14.1% margin and cut net leverage to 3.8x on $60.4M of free cash flow, and shares gapped +9.2%.…

APOL1 kidney precision-medicine story with clinical proof-of-concept in hand (Mar-25 HORIZON: 35.6% proteinuria cut, 61.8% in FSGS), but the tape has rolled over — $27.68, down 26% YTD and ~48% off the 52-wk high, no hard binary until…

Once-weekly canvuparatide's 1-yr Phase 2 durability (57% responders, 12 Jun) plus a cleared End-of-Phase-2 FDA path drove a +580% YTD re-rating into all-time highs. With the data catalyst spent, no dated binary inside 30 days, and an…

AI-data-center re-rating leg is unwinding — round-tripped from the $105.91 May ATH to the ~$84 50-day EMA under an unrebutted J Capital short thesis and a 2026-07-13 TD Cowen PT cut to $90; only the cyclical MCU/industrial recovery (~93%…

Theatrical-recovery narrative running hot: Q2 FY2026 beat (EPS $0.51 vs $0.33; revenue $231.744M vs $218.014M, 2026-07-30) plus a 12.5% dividend raise on 2026-08-04 carried MCS to within 1.5% of its 52wk high at RSI 87. The story is now…

Atlas re-acceleration (+29.4% YoY, record $117M seq add; Q1 FY27, 2026-05-28) is intact, but the +18.5% post-print breakout fully round-tripped from $444.72 to a $294.10 close as the AI-software theme sold on margin-timing fear. Sell-side…

Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low — so the trade is now a bump handicap, not a growth story. At…

Agentic-ad-infra narrative (Magnite Orchestration + Walmart Connect commerce-media) matured from a June breakout into a low-$20s plateau; Wells Fargo's 2026-07-17 neutral PT-nudge to $21 shows sell-side catching up, and the binary…

Operating leg accelerating into a de-rating tape: Q2 (2026-08-05) beat at $1.248B revenue / $3.30 adj EPS, Q3 guide $1.310–1.390B tops the $1.243B Street, leverage down to 3.0x — and the stock still fell 4.49% on the print and sits 31.4%…

ICE's $167.00 all-cash agreement signed 2026-07-30 converted MKTX into a spread instrument: the 2026-08-07 close of $162.53 leaves $4.47 gross against an H1 2027 guided close. The operating narrative is fully priced and the issuer has…

Cheap cyclical furniture reset that squeezed ~24% off its 2026-06-24 post-earnings low then STALLED flat ~$21.5 for three weeks under the $23.18 52-week high. Narrative is decelerating (Q4 orders -6.3%, backlog -10.8%), leadership is…

MakeMyTrip's mid-year recovery bounce has stalled: after reclaiming the 200-day near $55, MMYT rolled back to ~$49, below both the 50- and 200-day, straight into an August 3 Q1 FY2027 print where consensus models EPS down ~76% YoY on ~137x…

De-risked Wilson-disease NDA melt-up extended rather than sold the EAN news: a 6.70M-share float ran to fresh all-time highs (~$111 on 2026-07-17) on the June-30 FDA Rare Pediatric Disease designation and clustered analyst PT hikes. The…

Contracted AI-datacenter cooling story (>$4B Airedale agreement through 2029, $165M prepayment) is fundamentally intact, but a failed $323.25 breakout has unwound ~29%, lost the $260 base, and the theme has cooled to maturing. The…

Medicaid-margin-trough recovery, now fully re-rated: June's Illinois-win + BofA-double-upgrade breakout to ~$230 has matured into target catch-up (July raises to $230-250, but ratings stayed neutral and Barclays cut to $184). The whole leg…

Margin-led re-rate (Q1 FY27 GM 57.3%, +320bp; adj EPS $0.32 vs $0.08 est) is already priced at $38.65, ~3% off the $39.85 high after six weeks of chop. The live variable is the 2026-07-24 Section 122 expiry: the 10% Swiss-watch surcharge…

Record refining cracks are already in the tape: Q2 R&M margin $36.33/bbl vs $17.58 YoY and a 29% EPS beat on 2026-08-04, yet the stock closed 2026-08-07 at $298.20 — RSI 37.3, 6.7% under the $319.76 high — while six desks raised targets…

AI data-center power narrative still accelerating fundamentally (Enterprise Data ~2x YoY to $262.8M Q1; Q2 guide $890–910M, +35% YoY), but the tape bounced ~12% off the ~$1,200 shelf to ~$1,468 and now stalls at the 50-day into a binary…

Sympathy bid off the Micron-led memory supercycle and Russell 2000 inclusion floored the post-parabola markdown in the low-$20s, but the ~2026-07-28 Q2 print is now the binary: Everspin must show a non-casino datacenter/AI design win or…

The Aug 5 PDUFA resolved as an approval — mFLUSIVA is the first mRNA flu vaccine — and the tape did not break out: $59.17 on 2026-08-07, 27.7% under the 52-week high. Moderna guided to no meaningful 2026-27 season revenue, so the flu leg…

Post-COVID survivor re-rate has run its momentum leg and is now digesting a parabolic +31% push to a fresh 52-week high of $6.22 (June 26). Every driving catalyst is public, the move is idiosyncratic with no life-science-tools cluster…

AI-capex derating still in control and now colliding with a hostile print tape: Alphabet lost ~$294B on 2026-07-24 punished purely for AI spend, Tesla/Intel/Google all sold post-earnings, and MSFT reports Q4 FY26 on 2026-07-29 AMC below…

Housing-rebound-on-rate-cuts trade that carried MTH to a $85.38 52-week high has reversed: it lost the $75 June breakout shelf to $74.17 (-4.2% on 7/17) as mortgages held at 6.49% and Zelman capitulated to Neutral (7/7). Fundamentals still…

Beryllium critical-materials scarcity narrative still building, but the parabola cracked: a new ATH of $298.76 in early July gave way to a 5.6% reversal on 2026-07-07 to $247.20, now ~$258 and still ~9% above KeyBanc's $237 top target. The…

AI optical-interconnect arms-dealer with fundamentals still accelerating (FY26 DC growth guide >60%, Q3 guide $331-339M) but a July-broken chart: ~36% off the $418.90 high to ~$267 on the semi selloff, Russell Value index removal, and…

AI optical/interconnect re-rating is intact — PTs $105–125 (Stifel/Northland/Benchmark, 2026-06-25) versus a stock that ran ~$70→~$96.60 into late June — but the name now sits ~5 days from a binary Q2 FY26 print (~2026-07-23), retail…

Legacy plastics maker re-rated ~2.4x on a "Focused Transformation" — MTS distribution arm in discontinued ops, capital concentrated behind Signature/MegaDeck composite matting (Infrastructure orders +130% YoY, Q1 adj EPS $0.44 vs $0.28).…

Legacy hereditary-cancer testing house executing a diagnostics pivot; shares +40% off the June $3.99 base as Prolaris+AI launched (May 26) and Precise MRD colorectal/renal was pulled forward to Q3. Structure has repaired but now…

SolarWinds-spinoff MSP software vendor pivoting to cybersecurity via Adlumin MDR (26.7% of rev, +17.5% YoY); the cyber/MDR theme is accelerating but NABL's own tape is broken — ~40% off, ~$4.77 near the $2.92 base low after a soft Q2…

Recent IPO (Oct 2025, $25 price) running an AI-native travel-and-expense platform; growth reaccelerated to +34% YoY in Q1 FY27 with FY guide raised above consensus. But the tape cooled from $28.22 to ~$22 — the enterprise-AI-software theme…

Leveraged ~2x oil-beta proxy on the Hormuz war premium, +90% YTD near $100 but now rolling over: Susquehanna cut its target to $85 (2026-07-08) as the sell-side stops chasing, and the ~2026-07-23 Q2 print — the first to lap the premium —…

The June oil-tailwind cruise re-rating has matured and rolled over: July downgrades (Truist. Narrative velocity has reversed; the highest-beta name gives it back fastest.

Oncology-dx turnaround ACCELERATING — NGS +26%, PTEN IHC CDx (first FDA IHC companion dx in prostate, paired to AZ's TRUQAP) launched Jul 9, and TD Cowen $14→$19 / BofA $11→$16 on Jul 13 lifted consensus to ~$15.67, back above spot. But Q2…

Cyclical zinc-recovery confirmed and fully priced: Q1 EBITDA +126% YoY and Aripuanã's record 13kt ramp drove a run to the $16.89 high, but the equity now chops $12–13 while LME zinc printed a fresh 2026 high near US$3,622 — a bearish…

The IPO re-rate leg already failed — price sits 36.7% under the $18.45 52-week high. What is left is a margin/deleveraging story: Q1 adjusted EBITDA margin 21.0% against a 23.5–23.8% FY26 guide, funded by $70–80M of restructuring savings.…

Post-capitulation base off the $41.35 low is holding, but the estimate-revision direction has not turned. The 2026-07-22 decision to sever China distribution (Topsports online terminated 2027-01-01) deepens the near-term China reset even…

AI-networking legacy re-rate extending on a harder catalyst leg — first commercial AI-RAN platform with Nvidia (07-15) plus Taiwan Mobile, Orange Belgium and NestAI defense wins. Theme ACCELERATING, but the 2026-07-23 pre-open Q2 print is…

Genuine VAR margin-mix turnaround (Q1 GM +240bps, cloud GP +35%) but a derivative AI tag: hardware GP guided flat, sales +1%. Range-bound $102–123 since the early-June rejection; ~$110 already sits above the ~$103 street target with a…

Post-crash PEO turnaround: margin repair plus the Feb-2026 Workday HRScale launch drove a ~160% bounce off the $18.57 low, but worksite employees are still contracting (303k, -1% YoY) and the 2026-07-29 Q2 print is a hard binary. No…

Re-rating leg has stalled: NUTX closed $162.98 on 2026-07-17 after five straight down days, ~20% off the $204.00 high, giving back the June breakout that B. Riley's 2026-06-26 Buy/$290 initiation topped out. A $55.0M true-up of 18,950…

GSK's $124/share all-cash acquisition has closed: the tender expired 2026-07-14 with ~91.3% of shares tendered and accepted for payment, satisfying the minimum condition and triggering a Section 251(h) merger, Nasdaq delisting and SEC…

TRIDENT's OS miss (2026-06-18) killed the re-rating leg the 2026 markup was built on; JPM's 2026-07-13 reinstatement at Neutral/$17 confirms sell-side capitulating toward the ~$15-16 tape. A +12% YoY, loss-making single-asset device name…

Mid-July analyst cluster — JPM & Barclays Overweight PT $7, UBS Neutral PT $4.75 — has sell-side validating the Chris Peterson turnaround, and the tape pushed higher into 7/22. But a binary Q2 print lands before open 7/31, gating a full…

Legacy steel-pipe maker re-rated into a water-infrastructure + precast roll-up on a record $373M WTS backlog, an ~83% Q1 beat, and the Permalok RBJ field win. Narrative intact but the setup is extended — last near $148, ~35% above the…

Analog/auto up-cycle re-rate in an "AI beyond Nvidia" jersey: estimates rising (TD Cowen $340, B of A $310 on 7/13; Citi $370) into a broken tape — ~$266, down ~22% from the 5/27 ATH and ~12% below the $302 Street average, printing fresh…

Growth-compounder narrative is dead: Q1 first orders -50%, revenue -26%, and the $9.25→~$17.88 summer bounce has bled back to $14.12. The Q2 print slipped from mid-August to 2026-09-09, leaving a month with no dated catalyst and price…

Freight-cycle recovery in the top-margin LTL name is drawing a broadening upgrade cluster now printing above spot (Stifel $256 Jul 21, Truist $250 Jul 15, RJ $241 Jul 13), but growth is still rate and mix with tons/day negative. The…

Deep-cyclical carbon black where the 2024–25 tire-restock leg already failed (-32.5% from the $10.72 52-week high). What is left is a trough-and-deleverage read: Q2 2026 adj. EBITDA $58.2M (+26% sequential, -15% YoY), FY26 guide reaffirmed…

Reimbursement-reversal re-rate has already been spent: CMS restored pre-May-18 bone-growth-stimulator rates (reported 2026-07-02) and the 2026-08-05 Q2 print beat on both lines with FY26 guidance raised to $845–855M / $95–98M adj EBITDA —…

Takeover binary is resolved and deal-pinned: OGN trades ~$13.51 into Sun Pharma's $14.00 all-cash offer, a ~$0.49 (3.7%) gross spread. The 2026-07-06 disclosure suit was mooted by 2026-07-17 supplemental proxy filings, clearing the path to…

Closed by event: the Henkel all-cash takeout completed and OLPX was delisted from Nasdaq on 2026-07-07, with each share converted into the right to receive $2.06 cash. There is no longer a listed security, no price series, and no thesis to…

Post-CHMP-rejection repair, not a new leg: shares have clawed back from the 2026-06-26 gap low of $8.67 to roughly $9.69 on the J1289 J-code going live 2026-07-01. The 2026-08-13 Q2 print is the whole trade — consensus ~$11.6M net sales…

The AI-power re-rate is unwinding, not consolidating: ON closed $87.37 on 7/17, below the 6/26 Synaptics deal-gap floor, with targets cut twice in three weeks (TD Cowen to $95 on 7/13, Mizuho to $125 on 7/1). Merger-arb supply plus a fixed…

Counter-UAS order cadence is accelerating — $6.9M Australian DoD (07-20) plus $70M platform-wide orders (07-22) stack on June's $40M+ — and heavy short interest keeps ONDS on squeeze screens. But the roll-up is funded by serial share…

Early-July retail squeeze is broken: OPEN lost the $4.88 insider shelf and $4.50 base, fell ~12% to $3.88 on 2026-07-24 on a technical breakdown plus fresh housing weakness, into an Aug 4 Q2 print. A rolled-over meme trading into an…

Post-Chapter-11 reorg equity: emerged 2026-06-17, ~$714M debt wiped, distressed funds (Helix, Redwood) now hold the ~22M-share float. Shares ripped +11%/month into RSI 78.5 on thin volume ahead of the first post-reorg print ~2026-07-29 — a…

mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is…

FY27 guided as a reinvestment year: revenue $5.135–5.185B versus FY26 actual $5.246B, adj EBITDA margin 32–33% versus 36.3%, funding $100–200M of growth spend. The AI-data-foundation re-rating has not arrived; what remains is $807.5M FY26…

Oatly doubled its FY2026 constant-currency revenue growth guide to 8–10% from 3–5% on 2026-07-22 and printed positive adjusted EBITDA (+$0.4M). The re-rating leg is roughly two weeks old, RSI is 71, and no company catalyst is scheduled…

Squeeze leg broke: +43% in four sessions to a $63.79 high, then management priced 3.62M shares at $55.22 (~8% discount) and closed ~$191.9M net on 2026-07-06. Price round-tripped to $37.04, under the 20- and 50-day and under the $49…

Private-credit-stress bottom trade: OCIC redemption requests fell to 18.8% of shares in Q2 from 21.9% in Q1 and FRE rose 9% YoY to $392.2M at the 2026-07-30 print, driving a ~25% bounce off the 2026-07-10 FT/UBS-exodus low. The re-rating…

Dry-bulk recovery is in the P&L but not the tape: Q1 2026 (2026-05-11) adjusted EBITDA +70% YoY to $25.2M on $15,252/day TCE, yet the stock closed $7.42 on 2026-08-07, 20.1% under the $9.29 52-week high. The 2026-08-10 Q2 print is the…

Independent refiner ripping on a record 3-2-1 crack spread (~$70/bbl, 2026-07-16) and the Iran/Strait-of-Hormuz premium; sell-side chasing with PT hikes to $80–85. Narrative accelerating, but price sits at the 52-week high on peak-cycle…

Beaten-down bill-pay compounder: Q1 2026 revenue +30.2% YoY yet shares carved a $20.11 June 52-week low on margin-mix fear. Now ~40% off that low into a binary ~Aug-4 Q2 print — the read is a recovering base, not a chase.

Automation-and-buyback operating-leverage story re-rating a de-rated HCM name: Q2 (2026-08-05) beat revenue $531.2M vs $513.1M and EPS $2.78 vs $2.38, FY26 guide lifted to $2.197–2.212B, nine targets raised 2026-08-06. Leg is fresh, but…

Rumor is now a signed contract: Nuvei's $7.40 all-cash take-private (announced 2026-06-15, close mid-2027) pins PAYO near the $7.12 close as pure merger-arb. Only ~4% spread left to the deal vs ~28% air to the $5.14 standalone base; the…

Pure merchant refiner, the highest-beta play on crack spreads. Narrative is a refining-margin shock — ~10% of global capacity reported offline plus renewed Hormuz tensions — driving a fast sell-side PT re-rate ($39→$58 in 19 days). But it…

PBI broke the $17.62 shelf to a fresh 52-week high $18.62 (Jul 16) — the buyback/cost-cut re-rate is now extending, not consolidating. But revenue still shrinks ~3% YoY, consensus PT $16.43 sits below spot, and Q2 prints after close Jul…

Post-dilution repair story: the June 10–15 raise (~$145M equity + $287.5M 4.75% converts, ~$11.08 conv) roughly halved the stock to ~$8 while the commercial ramp (Q1 record 8.4M-lb output, +161% revenue) held. The 2026-07-15 Mitsui/RM…

Yield-analytics software re-rated on a real margin step — operating margin ~18%→25%, Platform revenue +36% YoY (Q1 reported 2026-05-07) — but the ~+280% run peaked at $69.05 on 2026-07-02 and flushed 11.5% intraday; the name is now…

Travel-reopening re-rate has largely run: after tagging a 52-week high near $19.75, the sell-side cluster completing 2026-07-17→23 kept Underweight/Neutral ratings (Morgan Stanley $13, Barclays $15) and merely marked PTs to the tape. The…

Post-correction RAIN RFID recovery has extended to $138.37 (2026-07-17), holding the reclaimed $128 April gap-fill and pressing the $144.57 post-earnings high — but the entire near-term read is the 2026-07-29 Q2 print (guide $103–106M, EPS…

Recovery leg re-fired: $66.06 (2026-06-05) → $71.49 on 2026-07-15 (+5.9%) → $73.20, back within 3% of the $75.25 high and ~6% ABOVE the $68.80 consensus target. Wells Fargo's 2026-07-10 note flags June financing data accelerating into a Q2…

Reopening re-rate has matured: PK ground to a fresh 52-wk high ~$15 while the sell-side fades — Wells Fargo cut to Equal Weight $15, JPMorgan Underweight $13, Morgan Stanley $11, all at/below the tape. A fresh entry chases new highs at the…

Levered small-cap industrial re-rating on AI/electrical-infrastructure demand: the 2026-08-05 Q2 beat (adj EPS $0.93 vs $0.81) plus a second FY26 guidance raise took price to a 52-week high at $52.51 with RSI(14) 89.3 and no dated…

Failed turnaround grinding at 52-week lows — $9.87 close, sitting on the $9.40 low. The 2026-06-15 binary resolved bearishly (comps -5.4%, EPS $0.16 vs ~$0.60 consensus) and the June squeeze fully round-tripped. No momentum, no catalyst…

Grid/AI-power second-order narrative has matured to broadcast coverage and rolled over: the June breakout failed (-21% off the $414.35 ATH to $327.43), Russell Value deletion pulled the mechanical bid, and a 2026-07-31 Q2 print at ~47x…

Sell-side discovery leg is spent: three Strong Buys with a $30.67 average against $28.68 (2026-07-17) leaves ~7% to consensus. The July 13 warrant redemption cleared the last dilution overhang, but the de-risking AFib endpoints are 2027…

Special-situation setup: an April-2026 strategic review (Morgan Stanley engaged) puts a possible sale on a controlled, down-~90%-from-IPO name, while record DTC revenue (+62.8% YoY) and Disney Solitaire drove a Q1 guidance raise. The Aug 6…

The +475% hydrogen-comeback squeeze has broken: the $3.12 Q1 gap and the 50-day both failed, price is ~$2.17 (-20% in 30d), and Susquehanna cut its target $3.75 → $2.50 on 2026-07-10. The June 30 NY Gateway close resolved as a restructure…

The 800VDC AI-power re-rate has cracked. POWI lost the $74–78 May breakout shelf in a -20% week to $70.45 (2026-07-17) and now sits below the $76.20 average target for the first time since spring. The GaN cohort broke with it — NVTS is…

Record order book keeps accelerating (Q2 orders +97% YoY to $490M, 1.7x book-to-bill, $1.8B backlog, plus a >$400M post-quarter data-center order; Q3 EPS revised UP to ~$1.47) while the tape has broken ~29% off the May high into a MATURING…

Rig-reactivation cyclical is basing, not broken: June averaged 95 US rigs (vs ~90 Q2 guide), the July EIA STEO lifted 2026 Henry Hub to $3.67, gas rigs turned up 122→126, and Piper upgraded to Overweight 07-14. Price bottomed $8.57 (07-01)…

Post-Russell momentum squeeze in a recent-IPO e-commerce compounder has broken — down ~25% from the $29.80 high to $22 in four sessions on a macro tech rout plus a Bear Cave short report. Fundamentals intact (raised FY guide, 127% NRR) but…

Ad-tech SSP growth-inflection re-rating: Q2 2026 revenue $78.6M, +11% YoY, first double-digit quarter after three declines, with a Q3 guide of $75–77M vs $71.1M consensus. The 2026-08-06 print repriced the stock to a 52-week high $17.78…

Post-print wreckage, not a turn. FY26 EPS held only via a ~$100M one-time tariff refund while the revenue guide went flat (2026-06-03, −25% overnight); BofA capitulated to Underperform/$70 on ~50% EMEA exposure (2026-06-25). The bounce to…

Deal-rumor re-rate has already run: $13.79 (Jun 26) to $17.38 (Jul 17), +75% off the $9.92 low, on an unsigned ~$1.5B point-of-care divestiture. Sell-side chased it up (Citi $13→$18). The Aug 4 Q2 print is the binary, and a shrinking base…

Not a momentum name — a thinning merger spread. Skyworks buys Qorvo for $32.50 cash + 0.960 SWKS; with SWKS ~$61 the implied value is ~$90–93 against QRVO ~$88, leaving 3–4% for underwriting China SAMR. The 2026-07-28 Skyworks print…

The eFPGA/defense royalty squeeze has fully unwound: QUIK is ~$13, roughly 47% below the $24.33 June high, and the $18 shelf broke exactly as the Russell inclusion passed. July's post-quantum IP announcement drew no bid — good news into no…

FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA — the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on…

Merger-arb stub, not a momentum vehicle: the Publicis $38.50 all-cash deal now has a dated shareholder vote (2026-08-17, 66⅔% threshold) and HSR filed 2026-06-11. At ~$37.82 the remaining spread is ~1.8% into a year-end close, against…

The +50% June reset rally round-tripped from ~$33.46 to $28.62 (2026-07-21), parking price back on the breakout shelf ahead of two binary FDA decisions: DTX401 (GSD Ia) PDUFA Aug 23 and UX111 (Sanfilippo A) PDUFA Sep 19. The July 30 Q2…

Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary — it needs a DAU…

Broken gene-therapy rebuild bleeding toward its 52-week floor while waiting on binaries: KRESLADI (LAD-I) approved with a Q4 2026 launch and a closed $180M PRV sale fund it, but the re-rate is the undated H2 2026 RP-A501 Danon update — a…

Post-SpaceX-IPO deflation broke RDW to a 2026-07-18 low near $8.51 (~67% off the 5/28 record). A relief bounce on Huntsville/Indiana facility news and $41.5M of H1 Stalker drone orders keeps running into a ~$850M dilution ceiling: the…

Luxury-resale turnaround has reached a durable adjusted-EBITDA inflection — FY2025 positive EBITDA all four quarters, Q1 2026 GMV +24%, FY guide raised — but the re-rate off ~$5 is largely spent and the tape is range-bound near $11.4. The…

Hypergrowth brokerage story has decelerated (Q1 rev +32% vs 70%+ historically, a forecast miss) and the stock sits near 52-week lows after the $880M RE/MAX deal spooked investors on dilution. The read is now a binary consolidation bet, not…

Consumer-discretionary rotation lifted a heavily-shorted luxury home-furnishings name; Goldman's Neutral upgrade (PT $155, 2026-07-08) marks the squeeze going public as CEO Friedman sold 125,000 shares into the pop — a maturing rotation,…

White-collar staffing in secular decline: Q2 EPS collapsed to $0.26 (2026-07-23) as AI automation and a frozen hiring market gut permanent-placement demand. The >5% dividend yield reads as a value-trap signal rather than a floor. No…

Q2 delivery beat and a RAISED FY output guide (2026-07-15) gave the recovery a fundamental leg, but the ~2026-05-27 death cross is uncured, the theme is a maturing consumer-discretionary tag-along, and the EV complex is heavy after Tesla's…

The oncology-pivot re-rate (0.55 to 8.00 in twelve months) has stalled: RLMD lost 10.5% on 2026-07-16 and another 4.0% on 2026-07-17 to $5.24, unwinding the Russell-inclusion bid with no dated NDV-01 catalyst before end-2026. Story intact,…

Memory theme is ripping — Micron +68% YTD with HBM sold out through 2027 — but Rambus has decoupled, down ~42% from its 2026-06-03 high of $174.10 to $101.44 while the cycle proxy sits near records. Interface content is a DIMM-unit story,…

Beaten-down UCaaS name popped ~24% on a 2026-07-23 Q2 beat-and-raise plus an OpenAI-adoption headline. But sell-side stayed Neutral (PTs $40–43), and the AI pivot is thin — internal adoption plus a hackathon, no attached revenue. Buying a…

Ex-growth cyber name (Q1 2026 rev -0.3% YoY; Q2 ARR guided to ~$820M) trading near $11 purely on a Jana-forced take-private; Goldman/JPMorgan shopping RPD to Advent/Bain/EQT. Newest sell-side PTs now cluster $9–11 at the tape as deal…

The sell-the-news break is now confirmed: RUM lost the $6.46–$6.66 100/200-day shelf and closed $5.76 on 2026-07-17, -19% from the post-rebrand tape and within 25% of the $4.62 52-week low. Every moving average is overhead. The 2026-08-10…

Post-interim re-rating has fully decayed: $4.61 on 2026-07-17 vs the $5.14 late-June high, with no dated event between here and the upLIFT full topline in 2H-2026. A binary rare-disease name in its dead zone — the 6/8 responder signal is…

June's +20% deleveraging bounce has fully round-tripped: $1.99 (6/26) back to $1.73 (7/17), now under the 50-day near $1.79 after failing exactly at the $1.99 consensus PT. Balance sheet is fixed, narrative is not accelerating, and a…

All-cash $105 Mapfre buyout signed 2026-07-23; the +37.58% announcement gap already fired, so SAFT is now a ~4.6% merger-arb spread into a Q1 2027 close — capped upside, binary Massachusetts-regulatory downside to the ~$73 unaffected…

GPU-normalization narrative broke at the 2026-07-30 print: revenue and adjusted EPS beat consensus, but adjusted EPS fell 17% YoY, franchised segment income −23%, and EchoPark FY26 GPU guidance was cut ~$300 at the midpoint. Shares…

Agentic-identity story intact and the post-earnings flush is basing: SAIL clawed from a $13.33 low (6/22) back to $15.68 (7/17), a higher low off the $10.30 bottom. Growth decelerated (ARR +26% vs +30%) and guidance was only affirmed, so…

Type-1-diabetes functional-cure narrative: UP421's no-immunosuppression islet transplant is still producing insulin at 14 months (n=1), de-risking SC451's IND guided "as early as 2026." Rare-disease cell therapy is accelerating, but the…

Legacy-EMS AI re-rate (AMD/ZT Systems datacenter manufacturing) blew off to a $282.72 ATH then corrected ~16% off the highs; the est. ~2026-07-27 FQ3 print is now ~9 days out and is the binary — it tests whether FQ2's +102% YoY surge was…

The mania leg broke in July — the $6.33 shelf and the $4.97 range low both went — and the 2026-08-05 Q2 print handed the name a different story: revenue $15.9M (+259% YoY) vs $9.6M consensus, plus the first positive operating income and…

The ETH-treasury flywheel is inverted: mNAV 0.81x (The Block, 2026-08-08) means any share issuance dilutes ETH-per-share, so the only live legs are buyback-driven discount closure and a new fee business (Galaxy SharpLink Onchain Yield…

Only year-long implantable CGM, clinically de-risked at ADA 2026 with revenue +71.9% YoY TTM — and the tape has spent six weeks grinding back toward the $4.79 post-catalyst low ($5.11 on Jul 17). Accelerating fundamentals against a broken…

Oral-GPCR platform narrative has cooled from accelerating to maturing: a marginal new high at $38.04 (2026-07-11) failed and the tape faded ~13% to $33.10 by 2026-07-24 into a catalyst vacuum. The first real binary (SEP-479 Phase 1) isn't…

Online-styling turnaround printed a 5th straight growth quarter and first sequential client gain (Q3, 2026-06-10) with a raised FY guide, but the post-print pop has fully round-tripped to ~$3.58 (2026-07-24) onto the $3.50 shelf, a second…

Cyclospora outbreak crushed SG from ~$9 to $6.15 (Jul 16) on guilt by association; FDA traceback cleared it Jul 17 (source: Taylor Farms iceberg at Taco Bell), sparking an 18% bounce to ~$7.08. Now below the $7.92–$8.43 consensus with…

April denifanstat/acne breakout round-tripped to the $6.00 Series A offering floor; SGMT bases near $7 (last close $7.06, 2026-06-26) with no trend. Dermatology pivot (China NMPA acne NDA accepted Dec 2025, US IND due mid-2026) is real but…

Tariff-recovery leg has stalled into a $39.71–$47.11 range with insiders selling every rally and zero buys; the whole story now hinges on the confirmed 2026-07-30 Q2 print. Consensus targets sit at or below spot ($43.75, 07-16), adjusted…

SI-joint-fusion medtech at a profitability inflection with a new Smith+Nephew pelvic-trauma distribution leg; tape has firmed to a base but stalls under the ~$17 200-day shelf it hasn't reclaimed. The confirmed 2026-08-03 Q2 print is the…

Dead sentiment vehicle in the give-back phase: the Russell add faded, SPCX public since 2026-06-12 gutted the SpaceX-proxy premium, and CFO turnover (Khalili effective 2026-07-27) lands right after ~$158.5M of dilution. Round-tripped from…

MEMS-timing picks-and-shovels story is fundamentally intact — Q1 datacenter revenue +158% YoY to 67% of sales, Renesas timing deal closed July 1 — but the momentum leg has broken: ~$550 on July 18 is ~39% off the May 11 all-time-high close…

Korea AI-infra narrative is loud while the ADR bleeds: $46.00 (06-02) to $30.62 (07-17), and both the 15GW plan (07-05) and JPMorgan's Overweight upgrade (~07-16) failed to hold a bid. The story flipped from AIDC margin accretion to ₩140T…

Specialty E&S compounder printing 20%+ operating ROE with the Apollo Lloyd's book integrated; the low-$40s-to-$63 re-rate is MATURING. The Aug 4 Q2 print is the next binary — a fresh chase near $60, up +17% in 30 days with earnings inside…

Post-Sarepta DMD gene-therapy vacuum trade: SGT-003 clean across 40 dosed (~110% microdystrophin) vs Elevidys's liver-death collapse. Ran ~+200% to a $11.45 high, then gave back ~29% into the $8 shelf; the overdue mid-2026 INSPIRE data +…

A record short squeeze (~32% of float) and buyout speculation, now joined by sell-side PT hikes (Alliance Global $10→$25, Jul 17), have carried SLS to a $16 test and back to ~$13; the defining Phase 3 REGAL overall-survival readout stays…

Dilution leg has broken the story: the $7B raise cleared at $27.50 on June 11 and spot is $24.18, with a live $2B ATM as forward supply. DDR contract prices +32% QoQ crush a business guiding 8.2–8.4% gross margin. Falling knife under all…

Single-asset ivonescimab binary sitting $1.26 above its $12.55 52-week low with going-concern language on the record. The narrative leg is dead but the funding question changed shape: co-CEO Duggan bought 3.81M shares at $13.12 on Jun 12…

AI-interconnect fundamentals still accelerating (Q1 FY27 data center +85% YoY, Needham reiterated Buy/$200 on 2026-07-13), but the price leg has broken: -22.7% in a month to ~$125, through the 20- and 50-day, ~30% off the $177.35 high.…

Since MIMEDX's 2026-07-29 definitive agreement ($33.00 cash + 0.4735 MDXG shares, ~$35 headline, ~$350M EV), SMTI trades as a merger-arb instrument rather than a wound-care growth story. At $34.10 (2026-08-07) the gross spread to computed…

Legacy web-analytics SaaS (IPO $22, now ~$7) repositioning as an LLM-data supplier: a seven-digit AI training-data contract (disclosed 2026-05-18) plus AI Agents launch is the re-rating story. But Q1 2026 growth decelerated to +10% YoY and…

AR-pivot narrative is broken and sells on every catalyst; five desks compressed targets to a $5 wall (UBS, Mizuho, Wells, DA Davidson $5; Goldman $6) into a hardening child-safety litigation wall. A legacy-pivot restructuring without a…